synaptic plasticity in basal ganglia output neurons …€¦ · synaptic plasticity in basal...
Post on 15-Aug-2020
8 Views
Preview:
TRANSCRIPT
SYNAPTIC PLASTICITY IN BASAL GANGLIA OUTPUT NEURONS IN PARKINSON’S DISEASE PATIENTS
by
Ian A. Prescott
A thesis submitted in conformity with the requirements
for the degree of Master of Science
Graduate Department of Physiology
University of Toronto
© Copyright by Ian Prescott (2009)
ii
SYNAPTIC PLASTICITY IN BASAL GANGLIA OUTPUT NEURONS IN PARKINSON’S DISEASE PATIENTS Master of Science 2009, Ian Prescott, Department of Physiology, University of Toronto.
ABSTRACT
Parkinson’s disease (PD) is characterized by the loss of dopamine in the basal ganglia
and leads to paucity of movements, rigidity of the limbs, and rest tremor. Synaptic
plasticity was characterized in the substantia nigra pars reticulata (SNr), a basal ganglia
output structure, in 18 PD patients undergoing implantation of deep brain stimulating
electrodes. Field evoked potentials (fEPs) in SNr were measured with one
microelectrode using single pulses from a second microelectrode ~ 1 mm away. High
frequency stimulation (HFS – 4 trains of 2s at 100Hz) in the SNr failed to induce a
lasting change in test fEPs amplitudes in patients OFF medication. Following L-Dopa,
HFS induced a potentiation of the fEPs that lasted more than 150s. Our findings suggest
that extrastriatal dopamine modulates activity dependent synaptic plasticity at basal
ganglia output neurons. Dopamine medication state clearly impacts fEP amplitude, and
the lasting nature of the increase is reminiscent of LTP-like changes, indicating that
aberrant synaptic plasticity may play a role in the pathophysiology of PD.
iii
ACKNOWLEDGEMENTS First, I would like to thank Dr. Bill Hutchison and Dr. Jonathan Dostrovsky for
their mentorship, guidance and support during my Master’s programme. I extend my
gratitude to Dr. Robert Chen, Dr. Melanie Woodin and Dr. Damien Shin for their helpful
academic advice, as well as Dr. Andres Lozano and Dr. Mojgan Hodaie for their time
and patience in the operating room.
I would like to acknowledge the financial support of Ontario Graduate
Scholarship in Science and Technology (OGSST) and the Vision Science Research
Program (VSRP) at Toronto Western Hospital. The work was also supported by the
Parkinson Society Canada Pilot Project (WDH) and the Canadian Institute for Health
Research (JOD).
I would also like to thank my fellow lab mates Luka Srejic and Arun Sundaram
for their collegial help and encouragement.
iv
LIST OF FIGURES Fig. 1 Direct and Indirect Pathways of the Basal Ganglia ....................................................5
Fig. 2 Centre-Surround Model of Basal Ganglia Function ..................................................11
Fig. 3 Basal Ganglia Dysfunction in PD as Predicted by the Rate Model ..........................18
Fig. 4 Mechanisms for Changes in Synaptic Transmission during LTP .............................28
Fig. 5 Microelectrode Apparatus .........................................................................................47
Fig. 6 Example Neuronal Traces .........................................................................................48
Fig. 7 HFS Stimulation Protocol .........................................................................................50
Fig. 8 Field Amplitude Test Locations ................................................................................54
Fig. 9 Depth Profile of SNr in PD Patient while ON Medication .......................................55
Fig. 10 Post Stimulus Time Histograms of SNr Neuronal Firing in PD .............................57
Fig. 11 Firing Rate of a SNr Cell during fEP Amplitude Measures ....................................58
Fig. 12 Paired Pulse Measures .............................................................................................60
Fig. 13 L-DOPA treatment of a Parkinsonian Patient Restores Plasticity ..........................62
Fig. 14 L-DOPA treatment of a Parkinsonian Patient Enhances Plasticity .........................63
Fig. 15 Dopamine Enhances Synaptic Plasticity, Population Data .....................................65
Fig. 16 Plasticity at Basal Ganglia Output...........................................................................70
Fig. 17 Aberrant Plasticity in L-Dopa-Induced dyskinesia .................................................78
LIST OF TABLES Tbl. 1 Patient Characteristics ...............................................................................................43
v
Abbreviations cAMP – Cyclic Adenosine Monophosphate CRE – Ca2+/cAMP responsive element CREB - Ca2+/cAMP responsive element binding protein DBS – Deep Brain Stimulation EPSC – Excitatory Post Synaptic Current fEP – Field Evoked Potential GABA – Gamma-Aminobutyric Acid GPe – External Segment of the Globus Pallidus GPi – Internal Segment of the Globus Pallidus HFS – High Frequency Stimulation L-Dopa - Levodopa LFS – Low Frequency Stimulation LIDs – Levodopa-Induced Dyskinesia LTD – Long Term Depression LTP – Long Term Potentiation MEP – Motor Evoked Potential MSN – Medium Spiny Neurons PAS – Paired Associative Stimulation PD – Parkinson’s Disease PPN – Pedunculopontine Nucleus SC – Superior Colliculus STN – Subthalamic Nucleus SM - Sensorimotor SNARE – soluble N-ethylmaleimide attachment protein receptor SNc – Substantia Nigra Pars Compacta SNr – Substantia Nigra Pars Reticulata UPDRS – Unified Parkinson’s Disease Rating Scale
vi
1 INTRODUCTION........................................................................................................ 1
1.1 General Introduction ........................................................................................ 1 1.2 Basal Ganglia ..................................................................................................... 3
1.2.1 Direct Pathway .......................................................................................... 6 1.2.2 Indirect Pathway ....................................................................................... 7
1.2.2.1 Substantia nigra pars reticulata .......................................................... 8 1.2.3 Additional Models of Basal Ganglia Function ..................................... 10
1.2.3.1 Centre-Surround ................................................................................. 10 1.2.3.2 Connectivity Model ............................................................................. 12
1.2.4 Movement Disorders ............................................................................... 12 1.3 Parkinson’s Disease ........................................................................................ 13
1.3.1 Etiology .................................................................................................... 14 1.3.2 Models of Parkinson’s Disease ............................................................... 16
1.3.2.1 Rate Model ........................................................................................... 16 1.3.2.2 Oscillatory Model ................................................................................ 19
1.3.3 Current Treatments ................................................................................ 20 1.3.3.1 Dopamine Therapy ............................................................................. 20 1.3.3.2 Deep Brain Stimulation ...................................................................... 22
1.4 Synaptic Plasticity ........................................................................................... 24 1.4.1 Long-term potentiation .......................................................................... 25
1.4.1.1 LTP Mechanisms ................................................................................ 26 1.4.2 Long-term Depression ............................................................................ 30
1.4.2.1 LTD Mechanisms ................................................................................ 30 1.4.3 GABAergic Plasticity .............................................................................. 32 1.4.4 Synaptic Plasticity in the Basal Ganglia ............................................... 34 1.4.5 Measuring Plasticity in Human Subjects .............................................. 37 1.4.6 LTP and LTD as Models for Behaviour ............................................... 38
2 OBJECTIVE & HYPOTHESIS ............................................................................ 39 2.1 Objectives......................................................................................................... 39 2.2 Hypotheses ....................................................................................................... 40
3 METHODS .............................................................................................................. 41 3.1 Patients ............................................................................................................. 41 3.2 Surgery ............................................................................................................. 44 3.3 Intraoperative Microelectrode Field Evoked Potentials & Neuronal Recordings ................................................................................................................... 45 3.4 Stimulation....................................................................................................... 49 3.5 Analysis of Neuronal Activity ........................................................................ 51 3.6 Statistics ........................................................................................................... 52
4 RESULTS ................................................................................................................ 53 4.1 fEP Test Sites ................................................................................................... 53 4.2 Field Potential Characteristics ....................................................................... 55 4.3 Paired Pulse Response .................................................................................... 59 4.4 DA Modulation of Synaptic Plasticity in the SNr in PD Patients ............... 61
5 DISCUSSION .......................................................................................................... 66 5.1 Inhibitory Nature of the Field ........................................................................ 66
vii
5.2 Dopamine and GABA Release ....................................................................... 67 5.3 Dopamine and Plasticity at the Basal Ganglia Output ................................ 68 5.4 Plasticity and Motor Behaviour ..................................................................... 71 5.5 Possible Mechanism for Dopaminergic Modulation of Plasticity in SNr .. 72 5.6 Applicability of Findings to the GPi .............................................................. 74
6 CONCLUSION ....................................................................................................... 76 7 FUTURE STUDIES ................................................................................................ 76
1
1 INTRODUCTION 1.1 General Introduction
Parkinson’s disease (PD) is a hypokinetic movement disorder characterized by the
loss of dopaminergic projections from the substantia nigra pars compacta (SNc) to
various targets, including the striatum, the input of the basal ganglia. Reduced
dopaminergic input to the striatum is thought to ultimately result in increased neuronal
firing of the inhibitory basal ganglia output and disturbed firing patterns with increased
synchronization (Albin et al., 1989;Brown, 2003;DeLong, 1990;Levy et al., 2002). Such
changes bring about bradykinesia, rigidity, tremor, and postural instability, although the
underlying mechanisms leading to these symptoms are still poorly understood. Currently,
levodopa (L-Dopa) administration is the most common and effective therapeutic
treatment. However, long-term L-Dopa treatment is not without its own serious side
effects. Abnormal involuntary movements (dyskinesias) are motor complications that
develop following prolonged treatment in the majority of PD patients (Obeso et al.,
2000a;Obeso et al., 2000b).
In addition to its dopaminergic nigrostriatal projections, the SNc also sends
ventrally projecting dendrites to the SNr (Cheramy et al., 1981;Geffen et al., 1976;Korf et
al., 1976;Robertson et al., 1991). However, little is known of the effects of dopamine
released from these ventral SNc projections, either in animal models or humans, despite
the fact that basal ganglia output structures seem intimately tied to dyskinesia. Deep brain
stimulation (DBS) in the subthalamic nucleus (STN), a basal ganglia structure that sends
glutamatergic projections to the SNr and GPi, has proven remarkably efficacious as a
2
treatment of PD and L-Dopa induced dyskinesia (Kleiner-Fisman et al., 2006;Perlmutter
and Mink, 2006). While STN DBS does not provide a greater degree of benefit for PD
symptoms than optimal therapy with L-Dopa (Krack et al., 2003;Pahwa et al., 2005), it
does lessen the time a patient spends in the “OFF” state when the benefit from an
individual dose of medication has diminished, and permits the reduction of dopaminergic
medications and their adverse side effects including dyskinesia (Jaggi et al.,
2004;Kleiner-Fisman et al., 2006;Moro et al., 1999). DBS appears to mimic the effect of
beneficial lesions instead of exacerbating the hyperactivity in the basal ganglia output
neurons; however, the mechanism of action remains unclear.
Neurophysiological studies in corticostriatal slice suggest that abnormal
involuntary movements such as dyskinesia are the result of alterations to synaptic
plasticity at the basal ganglia input. Long term potentiation (LTP) at the corticostriatal
synapse can be induced with high frequency stimulation (HFS) and reversed with low
frequency stimulation (LFS) in healthy adult Wister rats (Picconi et al., 2003;Picconi et
al., 2008). LTP is absent in dopamine lesioned (6-OHDA) rats, but can be restored with
chronic L-Dopa treatment. Additionally, several paired associative stimulation (PAS)
studies have shown that motor evoked potential (MEP) amplitudes in the motor cortex of
PD patients are modulated by dopaminergic medication state and that these changes are
LTP-like in nature (Morgante et al., 2006;Ueki et al., 2006). PAS increased MEP
amplitude in controls but not in patients OFF medication irrespective of their dyskinesia
state. L-Dopa administration restored the potentiation of MEP amplitudes by PAS in non-
dyskinetic but not dyskinetic patients (Morgante et al., 2006). These findings indicate
that LTP-like plasticity is absent from the motor cortex in a dopamine deprived state and,
3
taken together, these studies in cortex and striatum suggest that a lack of LTP-like
plasticity caused by the absence of dopamine may play an important role in mediating the
disabling motor symptoms of PD. However, to this point, a suitable methodology for
direct measurement of synaptic plasticity in the human central nervous system has been
lacking (Cooke and Bliss, 2006).
The aim of this study was to characterize synaptic plasticity at the basal ganglia
output during in-vivo recordings in PD patients undergoing implantation of DBS
electrodes in the STN. Employing a novel methodology for evoking and measuring field
evoked potentials (fEPs) in SNr using a pair of microelectrodes, we found that the
amplitude of these positive fEPs was modulated both by tetanizing trains and L-dopa,
implicating extrastriatal dopamine actions in the pathophysiology of PD.
1.2 Basal Ganglia
The basal ganglia consist of a group of interconnected subcortical nuclei that
function in critical motivation, motor planning, and procedural learning functions
(Graybiel et al., 1994;Hikosaka et al., 2000;Yin et al., 2006). Neural circuits within these
nuclei form an integral part of the extrapyramidal motor system, and dysfunction of these
circuits is associated with many prominent neurological disorders including Parkinson’s
disease and Huntington’s disease (Albin et al., 1989;DeLong, 1990), as well as
psychiatric disorders such as obsessive-compulsive disorder (Aouizerate et al., 2004).
These subcortical nuclei, organized in a network fashion of stimulatory and
inhibitory connections and mediated by a range of neurotransmitters, are responsible for
4
the processing of cortical input. The primary structures are the substantia nigra pars
compacta (SNc) and pars reticulata (SNr), the striatum, the internal and external segments
of the globus pallidus (GPi and GPe), and the subthalamic nucleus (STN).
The most prominent model of basal ganglia motor circuit function was originally
proposed by (Albin et al., 1989) and (DeLong, 1990) and termed the rate model. Derived
from studying human movement disorders, this model is based on the segregation of
information processing into direct and indirect pathways, which act in opposing ways to
control movement (Figure 1). It describes two parallel cortico-basal ganglia-thalamo-
cortical loops that diverge within the striatum and are differentially modulated by
dopamine.
5
Figure 1 Direct and Indirect Pathways of the Basal Ganglia. In the direct pathway, transiently inhibitory projections from the striatum project to tonically active inhibitory neurons of the SNr and GPi, which project in turn to the VA/VL complex of the thalamus. In this pathway the striatum receives transiently excitatory projections from the cortex and substantia nigra. In the indirect pathway, transiently active inhibitory projections from the striatum project to the tonically active inhibitory neurons of the GPe. The influence of the nigral input the striatum is inhibitory in this pathway. The GPe projects to the STN which also receives an excitatory input from the cortex. The STN in turn projects to the GPi, where it transiently acts to oppose the disinhibition of the direct pathway,
6
1.2.1 Direct Pathway
Sensorimotor cortex (SM) activation results in excitation of the input structure of
the basal ganglia, the striatum, via glutamatergic corticostriatal projections. In the direct
pathway, the striatum, in turn, sends inhibitory gamma-aminobutyric acid (GABA)
projections to the output nuclei of the basal ganglia, the internal segment of the globus
pallidus and the substantia nigra pars reticulata (Figure 1). The direct pathway of the
basal ganglia is so termed because it directly links the input and output of the basal
ganglia with a single GABAergic projection. These output nuclei then send GABAergic
efferents to the ventrolateral thalamus, a structure responsible for motor control
(Dostrovsky et al., 2002;Parent and Hazrati, 1995a). Thus, SM cortical activity results in
excitation of striatal neurons, inhibition of the GPi and SNr, and disinhibition of the
motor thalamus since diminished output nuclei activity results in less inhibitory drive to
the thalamus
In addition to glutamatergic afferents from the cortex, the striatum also receives
dopaminergic projections from the SNc. Dopamine released in this region binds to the
dopamine D1 and D2 receptors, which are anatomically and functionally segregated
(Wooten, 2001) and involved in the direct and indirect pathways respectively. In the
direct pathway, binding of dopamine to D1 receptors has an excitatory effect on striatal
medium spiny neurons projecting to the output nuclei of the basal ganglia (Figure 1).
The D1 receptor subtype is a G-protein coupled receptor, and its activation
stimulates adenylate cyclase which in turn activates cyclic adenosine monophosphate
(cAMP) and associated cAMP-dependent protein kinases (Missale et al., 1998).
7
The GPi and SNr also send efferent projections to targets such as the superior
colliculus (SC), involved in oculomotor control (Sparks and Mays, 1990a) (Hikosaka et
al., 2000) and the pedunculopontine nucleus (PPN), a structure increasingly thought to be
involved in movement control (Pahapill and Lozano, 2000;Weinberger et al., 2008a).
1.2.2 Indirect Pathway
As its name implies, the indirect pathway connects the input of the basal ganglia
to the output via two secondary structures: the GPe and STN. In addition to the
striatonigral projections of the direct pathway, the striatum sends GABAergic efferents to
the GPe, which has inhibitory GABA projections to the STN (Figure 1). STN excitation
results in activation of glutamatergic efferents to the GPe and GPi (Kita et al.,
2004;Nambu et al., 2000). Thus, in this pathway, SM activation excites inhibitory striatal
projections to the GPe, which results in less GPe imposed inhibition on the STN,
allowing the STN to excite the output nuclei of the basal ganglia, thereby inhibiting the
premotor centres. Therefore the indirect pathway acts to inhibit movements and is in
opposition to the direct pathway.
As in the direct pathway, dopamine plays an important role in regulating activity
of the indirect pathway. However, unlike the direct pathway, dopamine has an inhibitory
effect on striatal medium spiny neurons projecting to the GPe. Binding of dopamine to
D2 receptors on striatal neurons that project to GPe results in cessation of GABA release.
Like its D1 counterpart, the D2 receptor subunit is a metabotropic G-protein coupled
8
receptor. In contrast with D1, activation of D2 receptors inhibits the formation of cAMP
by inhibiting adenylate cyclase (Missale et al., 1998)
One can thereby envisage that under normal conditions, the direct pathway serves
to inhibit the GPi/SNr and facilitate movement, while the indirect pathway tends to
prevent or slow movement. Cooperatively the two pathways are thought to regulate
thalamocortical neurons and allow movement to be controlled (Parent and Hazrati,
1995a).
1.2.2.1 Substantia nigra pars reticulata
The substantia nigra is a brain structure located in the mesencephalon that plays
an important role in reward, addiction, and movement. Substantia nigra is Latin for
"black substance", as parts of the substantia nigra appear darker than neighbouring areas
due to high levels of melanin in the dopaminergic pars compacta neurons (Francois et al.,
1984).
The pars reticulata of the substantia nigra (SNr), along with the internal segment
of the globus pallidus (GPi), are the major output nuclei of the basal ganglia. These cell
groups are primarily composed of GABAergic neurons and they integrate inputs from all
upstream basal ganglia structures (striatum, GPe, and STN). From rodents to primates
(including humans), the SNr and GPi innervate thalamic and brain stem nuclei connected
to motor, prefrontal, parietal and temporal associative cortical areas (see review by
Deniau et al., (2007) thereby allowing the basal ganglia access to control of motor,
cognitive, and emotional/motivational processes (Bar-Gad et al., 2003;Francois et al.,
9
1984;Francois et al., 2002;Takakusaki et al., 2003). As mentioned above, the SNr also
projects to the superior colliculus, which is implicated in orienting behaviour and
oculomotor functions (Hikosaka et al., 2000;Nakamura and Hikosaka, 2006a;Nakamura
and Hikosaka, 2006b;Sparks and Mays, 1990b), and to regions of the pontine tegmentum,
controlling postural tone and locomotion (Grofova and Zhou, 1998;Pahapill and Lozano,
2000;Takakusaki et al., 2004;Weinberger et al., 2008b). Although the precise input–
output relationships of SNr neurons remain to be clarified, the spatial distribution of
neurons within the SNr and the topographic organization of cortico-striato-nigral
projections suggest that the neuronal architecture of SNr provides a mechanism allowing
defined corticostriatal inputs to be directed to specific and functionally associated sites in
the thalamus, superior colliculus and tegmentum (Deniau et al., 2007).
Inactivation studies have tested how altered SNr activity contributes to
parkinsonian motor signs. Interestingly, intra-SNr injections of muscimol, a GABAA
receptor agonist, in the centrolateral region of the SNr improved limb akinesia and
bradykinesia in MPTP monkeys whereas injections in the medial region induced saccadic
eye movements (Wichmann et al., 2001). Additional results from this group have
demonstrated that, while neuronal responses in this region do not always respond directly
to passive or active movements, 21% of neurons show movement-related responses.
Further, a large proportion of neurons show responses that may be related to memory,
attention, and movement preparation (Wichmann and Kliem, 2004). Finally, additional
confirmation of the role of the SNr in movement comes from recent clinical DBS studies.
SNr stimulation in PD patients has been shown to significantly improve gait and balance
(Chastan et al., 2009).
10
1.2.3 Additional Models of Basal Ganglia Function
1.2.3.1 Centre-Surround
Mink has proposed a model in which the basal ganglia functions through a centre-
surround mechanism (Figure 2). This hypothesis is similar to the rate model in that it
supports the view that the basal ganglia can be separated into segregated direct and
indirect circuits (Mink, 2003). This model posits that the role of the indirect pathway is to
broadly inhibit basal ganglia output, while direct pathway activation is more specific and
leads to a focused facilitation and surround inhibition of motor programs in thalamus,
brainstem and cortex. The anatomical basis for this model is based on the observance of a
broad divergence of a single STN neuron onto many GPi/SNr neurons. When voluntary
movement is generated, cortical motor areas send a corollary signal to the STN which
causes widespread excitation of the GPi and SNr and subsequent inhibition of motor
pattern generators for competing postures and movements. Simultaneously, the motor
cortex sends signals to the striatum which filters and transforms those signals in a
context-dependent manner and then focally inhibits GPi and SNr to remove tonic
inhibition from motor pattern generators involved in the desired movement. The output of
the basal ganglia acts to focally select desired motor mechanisms and broadly inhibit
competing motor mechanisms to allow movement to proceed without interference (Mink,
1996).
11
Figure 2 Centre-Surround Model of Basal Ganglia Function. Excitatory (green) and inhibitory (red) projections are shown. Relative neuronal efferent activity is shown by thick (high) and thin (low) lines. Input to the striatum or the globus pallidus internal segment (GPi) or the substantia nigra pars reticulata (SNr) can either inhibit (grey) or excite (white) efferent inhibitory neurons. The action of subthalamic nucleus (STN) is also shown. Adapted from (Mink, 2003).
12
1.2.3.2 Connectivity Model
Using computational network models of the STN and GPe in the indirect
pathway, Terman et al. (2002) highlighted the role of the coupling architecture in the
network, and associated synaptic conductances, in modulating activity patterns displayed
within the network (Terman et al., 2002). In this connectivity model, depending on the
arrangements and strengths of synaptic connections within and between cellular
populations, different cell firing patterns emerge. These patterns can include clustering,
propagating waves, and repetitive spiking. The network can be switched from irregular
uncorrelated spiking to correlated rhythmic patterns by increasing striatal input while at
the same time weakening intrapallidal inhibition (Bevan et al., 2002;Terman et al., 2002).
Therefore, altering the dopamine level could have profound effects on network activity
since it could directly alter striatal activity. A shortcoming of this model is that it is
limited to a small sub-circuit of the basal ganglia, and as such, fails to predict how
changes in synaptic weights (e.g. caused by changes in DA levels) would affect the
output of the basal ganglia.
1.2.4 Movement Disorders
Much of the insight into basal ganglia function has been provided from studying
human neurological diseases that involve the basal ganglia. Movement disorders that
result from basal ganglia damage and/or dysfunction are often dramatic and, depending
on the site of the lesion, can cause extreme slowness of movement and rigidity, or
13
uncontrollable involuntary postures and movements (Mink, 1996). These diseases include
degenerative diseases like Parkinson’s or Huntington’s disease, destructive lesions
resulting from vascular accidents like hemiballismus, and a variety of conditions of
unknown cause that may arise through, for example, changes in synaptic communication.
1.3 Parkinson’s Disease
First described by James Parkinson in 1817, Parkinson’s disease is a progressive
neurological disease that affects multiple brain systems that regulate motor function,
mood, perception and cognition (Cummings, 1999;Parkinson, 1817). Affecting in excess
of 3% of people over the age of 65 worldwide (Zhang and Roman, 1993), PD has a mean
age of onset of approximately 60 years (Hughes et al., 1993) with 90-95% of PD cases
first manifesting symptoms after age 40 (Lang and Lozano, 1998a).
PD is characterized by the loss of dopaminergic projections from the SNc to
various targets, including the striatum, the input of the basal ganglia. Reduced
dopaminergic input to the striatum is thought to result in increased neuronal firing of the
inhibitory basal ganglia output and disturbed firing patterns with increased
synchronization (Albin et al., 1989;Brown, 2003;DeLong, 1990;Levy et al., 2002). It is
estimated that 60-70 % of dopaminergic neurons are lost by the onset of symptoms (Kish
et al., 1988;Lang and Lozano, 1998a).
The main symptoms of PD include: i) tremor at rest; ii) slowness of movement
(bradykinesia); iii) paucity of movement (akinesia); iv) muscular rigidity; and, v)
abnormally flexed posture with postural instability (Lang and Lozano, 1998a;Lang and
14
Lozano, 1998b). The manifestation of PD symptoms can be highly variable from one
individual to the next. Some may have severe bradykinesia with minimal rigidity, others
may have the opposite and still others may have both equally. The diagnosis of PD is
made on the basis of clinical criteria that evaluate the presence and asymmetry of these
symptoms and a good response to levodopa. However, definitive diagnosis of PD can
only be made through a post-mortem neuropathological examination, as there is no
biological marker to date that unequivocally confirms the presence of the disease (Lang
and Lozano, 1998b).
1.3.1 Etiology
The pathogenesis of PD remains unknown, but pathological, genetic and
epidemiologic evidence suggests that several etiologies may result in the PD phenotype.
Lewy bodies are eosinophilic hyaline inclusions that have been suggested to be
pathogenic because they are consistently observed post-mortem in selectively vulnerable
neuronal populations (Lang and Lozano, 1998a). However, some have argued that Lewy
body formation is not specific to PD and the pervasiveness of Lewy bodies has been
found to increase in non-PD brains with age (Gibb and Lees, 1988). This would seem to
argue against a causal relationship to PD, but it’s possible that Lewy bodies in non-PD
brains are a precursor to disease.
Excitotoxic mechanisms have also been implicated in SNc degeneration.
Excessive N-methyl-d-aspartate (NMDA) receptor activation can trigger, through a
cascade of events, augmented intracellular calcium concentrations, mitochondrial DNA
15
damage, and eventually cell death (Dawson and Dawson, 2004). These models are
consistent with findings of selective preservations of SNc dopamine neurons that are
capable of buffering changes in intracellular calcium levels (Damier et al., 1999;Lang and
Lozano, 1998a).
Other PD-pathogenic models propose that dysfunction in the electron transport
chain in mitochondria leads to reduced energy production and eventually to cell death.
This predisposes dopamine neurons to toxic insults or genetic deficiency and increases
the vulnerability of these neurons to apoptosis (Lang and Lozano, 1998a). These models
are supported by evidence that 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a
neurotoxin known to selectively kill dopamine neurons, inhibits complex 1 of the
electron transport chain (Beal, 2003). Furthermore, PD subjects show a 30-40 % decrease
in complex 1 activity in SNc (Mann et al., 1992).
Evidence supporting a genetic etiology for PD is derived from genotyping
kindreds with rare inherited forms of the disease. Certain gene mutations are associated
with PD, i.e. α-synuclein, LRRK2, parkin, DJ-1 and PINK. Autosomal dominant
mutations in α-synuclein lead to aggregation of α-synuclein proteins and is thought to be
the precursor for Lewy body formation (Cookson, 2005). Also inherited in an autosomal
dominant manner, LRRK2 is a protein kinsase and overactivity of protein kinases can
mediate neurotoxicity (Klein and Lohmann-Hedrich, 2007). Parkin is an E3 ubiquitin
ligase and a parkin mutation is thought to impair the ubiquitin-proteosome-mediated
hydrolysis of damaged or misfolded proteins (Cookson, 2005;Eriksen et al., 2005).
Therefore mutations in the parkin gene might cause accumulation of proteins, some of
which may be neurotoxic, and may also be causal for Lewy body formation. The gene
16
product functions of DJ-1 and PINK remain unclear but both appear to protect against
mitochondrial damage (Martella et al., 2009). Mutations in DJ-1 or PINK would render
dopamine neurons susceptible to mitochondrial damage, leading to cell death.
Finally, epidemiological studies have reported that living in a rural area, drinking
well water, farming, and exposure to pesticides may be risk factors for developing PD
(Priyadarshi et al., 2001), suggesting there are environmental factors found in rural
environments that may cause PD.
Despite a large body of work, PD remains an incurable, progressive, idiopathic
movement disorder with several suspected or implicated etiologies, the hallmark of which
is loss of dopamine neurons from the basal ganglia.
1.3.2 Models of Parkinson’s Disease
1.3.2.1 Rate Model
As mentioned above, the rate model of basal ganglia activity is based on the
segregation of information processing into direct and indirect pathways, which act in
opposing ways to control movement (Figure 1). Originally proposed by (Albin et al.,
1989) and (DeLong, 1990), the rate model was derived from studying animal models of
movement disorders and describes two parallel cortico-basal ganglia-thalamo-cortical
loops that diverge within the striatum and are differentially modulated by dopamine. In
PD, the rate model postulates that with the loss of dopaminergic input to the striatum,
there is a reduced drive in the direct pathway from the striatum to the output nuclei of the
basal ganglia, and an increased drive in the indirect pathway through GPe and STN.
17
These alterations in activity result in the increased activity of basal ganglia output nuclei,
ultimately resulting in the excess inhibition of thalamic and cortical activity which
impairs voluntary movements (Figure 2). This model predicts that parkinsonian
symptoms should be improved by the ablation or inactivation of the STN and GPi. When
this was proven to be the case in MPTP-treated monkeys (Aziz et al., 1992;Bergman et
al., 1990), these structure became key targets for DBS therapy (discussed in more detail
below).
However, the rate model appears incomplete as it fails to explain why a
pallidotomy, which reduces the inhibitory basal ganglia output to the thalamus, improves
symptoms for both hypokinetic and hyperkinetic movement disorders (Marsden and
Obeso, 1994). Additionally, anatomical studies in the basal ganglia have revealed i) a
subpopulation of MSNs that co-express D1 and D2 receptors (Surmeier et al., 1996), and
ii) striatal neurons projecting to the GPi and SNr can also send axon collaterals to the
GPe (Kawaguchi et al., 1990), suggesting that the direct and indirect pathways are not
completely segregated.
Furthermore, dopamine can have dramatic effects in regions of the basal ganglia
other than the striatum. Indeed, nigral dopamine depletion has been shown to impair
motor performance independent of striatal dopamine neurotransmission, while increased
nigral dopamine release can counteract striatal dopamine impairments (Andersson et al.,
2006).
18
Figure 3 Basal Ganglia dysfunction in Parkinson’s disease as predicted by the rate model. In PD, the dopaminergic inputs provided by the SNc are diminished (thinner arrows), making it difficult to generate the transient inhibition from the striatum. This ultimately results in an increased activity in the output nuclei leading to increased inhibition on the glutamatergic excitation of the motor cortex and a subsequent reduction in movement, observed in patients as bradykinesia.
19
1.3.2.2 Oscillatory Model
Popularized by Brown’s group in London, the oscillatory model of PD postulates
that excessive and oscillatory synchronization of neuronal activity occurs in the basal
ganglia in PD and that this activity has a predilection for the beta frequency band centred
around 20 Hz (Brown, 2003). This hypothesis has gained strength on the support of intra-
operative recordings in PD patients that demonstrate locking of neuronal discharges in
the STN to beta oscillatory local field potentials (Kuhn et al., 2005;Weinberger et al.,
2006;Weinberger et al., 2009). How this synchronization ultimately impairs motor
function is unclear but one idea is the “noisy signal hypothesis”. In the parkinsonian state,
only partial processing is possible in the basal ganglia as the synchronous activity
effectively acts as a disruptive ‘noisy signal’ and is worse than a fixed and unfamiliar
patterning of activity when passed on to other processing units like the cortex (Brown and
Eusebio, 2008).
Since this model’s inception, it has become clear that beta synchrony may relate
to some but not all elements of motor impairment in Parkinson's disease, and the jury is
still out on its quantitative importance and the means by which it might disturb motor
processing (Eusebio and Brown, 2009). One thing that seems reasonably clear, however,
is that beta synchrony is a good biomarker of the conventional akinetic-rigid state in both
patients (Hammond et al., 2007) and many animal models of parkinsonism (Costa et al.,
2006;Mallet et al., 2008b;Mallet et al., 2008a;Sharott et al., 2005).
An unresolved question is whether there is something particularly important about
certain frequencies of pathologically synchronized oscillation or whether it is the
20
oscillatory synchronization per se, rather than the precise frequency that is more relevant.
Most patients show evidence of synchronization in the beta frequency band, but this tells
us more about the resonance frequencies of circuits in the absence of dopaminergic input
than whether synchronization with a lower or higher frequency might be just as
pathogenic if it were to occur. Indeed, one report suggests that within certain limits (8–35
Hz), changes in synchronization rather than frequency correlate better with levodopa-
induced improvement in bradykinesia and rigidity (Kühn et al., 2009). At even higher
frequencies, however, there seems to be no antikinetic effect, but rather a possible
favouring of movement (Brown, 2003).
1.3.3 Current Treatments
1.3.3.1 Dopamine Therapy
The dopamine precursor levodopa (L-Dopa) was discovered in the 1960’s
(Cotzias et al., 1967) and remains the most effective drug for controlling PD
symptomatology. L-Dopa is typically administered orally in combination with a dopa-
decarboxylase inhibitor (such as benserazide or carbidopa) to prevent its metabolism
prior to crossing the blood brain barrier (Boshes, 1981). Once across this barrier, L-Dopa
is internalized by residual nigral dopaminergic neurons and converted to dopamine by
aromatic L-amino-acid dopa-decarboxylase. Once converted and packaged in vesicles,
dopamine can be released to stimulate dopamine receptors on post-synaptic striatal cells
(Thanvi and Lo, 2004) and restore some semblance of its original function. L-Dopa
significantly improves bradykinesia and akinesia (Vingerhoets et al., 1997) and also
21
improves, to varying degrees, rigidity and tremor, hypometria, the performance of
complex tasks, and the generation of internally cued movements (Beckley et al.,
1995;Benecke et al., 1987;Burleigh-Jacobs et al., 1997;Yuill, 1976).
An unfortunate side effect of L-Dopa usage is that patients typically develop
severe and uncontrollable motor fluctuations, called dyskinesias, after prolonged
exposure (Obeso et al., 2000a;Obeso et al., 2000b). L-Dopa-induced dyskinesias are
observed in the majority of patients who have been treated for 5–10 years with L-Dopa
(Schrag and Quinn, 2000). These motor complications are difficult to treat and become a
major contributor to disability in some patients. Why long-term use of L-Dopa results in
dyskinesias remains unclear (Dunnett, 2003). Dyskinesias could be the result of strong
compensatory processes by which the striatum adapts to disruption of the nigral
dopaminergic projections to the striatum (Zigmond et al., 1990), such as increasing
presynaptic dopamine release and the sensitivity of postsynaptic dopamine receptors on
striatal neurons (Ungerstedt, 1971;Zigmond et al., 1990). In this scenario, dyskinesias
would arise when agonist drugs or L-Dopa interact with sensitized receptors. However,
dyskinesias can develop independent of the level of denervation and receptor sensitivity
(Dunnett, 2003). Alternatively, dyskinesia may be the result of an aberrant form of
synaptic plasticity in striatal neurons, related to L-Dopa acting on the dopaminergic
regulation of plasticity at corticostriatal synapses (Calabresi et al., 2007;Centonze et al.,
1999;Picconi et al., 2003;Picconi et al., 2005), a hypothesis that will be expanded upon in
later sections.
One strategy to reduce the risk for motor complications is the use of dopamine
receptor agonists which have been proven safe and effective as initial therapy in early
22
stages of Parkinson's disease. However, it is still controversial whether the use of these
agonists must be started early, as opposed to initiation only after the L-Dopa
complications develop (Ahlskog, 2003). Dopamine agonists such as bromocriptine,
pergolide and apomorphine have a longer half life than levodopa and bind at post-
synaptic receptor sites independently of the dopamine terminal (Junghanns et al., 2004),
thereby reducing receptor sensitivity and the development of motor complications.
However, dopamine agonists are not without their own adverse effects, including nausea,
hypotension, hallucinations and edema.
1.3.3.2 Deep Brain Stimulation
Surgical treatment of PD using deep brain stimulation (DBS) can provide
additional help for selected patients whose symptoms are not controlled sufficiently by
medication. DBS has progressively replaced brain lesioning, such as thalamotomies and
pallidotomies, over the last 20 years (Limousin and Martinez-Torres, 2008). DBS in the
ventro-intermediate nucleus of the thalamus was the target for these early procedures, and
was performed contralateral to thalamotomies to reduce morbidity of bilateral
procedures, primarily on speech and balance (Benabid et al., 1987).
The procedure involves implantation of an electrode into the target region using
stereotactic neurosurgical techniques (detailed in (Lemaire et al., 2007). The electrode
lead is then connected with an extension wire to a programmable pulse generator that is
implanted below the clavicle. The stimulation parameters are programmed to achieve
maximal clinical benefit using non-invasive radio-telemetry. The clear advantage of DBS
23
over lesioning is that there is minimal destruction of brain tissue and the electrode can be
potentially removed or repositioned without creating permanent damage (Lozano and
Mahant, 2004).
While thalamic DBS provided a positive effect on tremor, it provided a limited
effect on other cardinal PD symptoms (Limousin and Martinez-Torres, 2008). This
limited effectiveness led to the application of the DBS procedure on new targets, the STN
and GPi. The GPi was chosen based on the noted similarities of the effect of a lesion and
HFS to the thalamus and the familiarity on the effect of pallidotomies (Laitinen et al.,
1992). The STN was chosen based on research on MPTP-treated monkeys; these animals
exhibited excessive STN activity (Bergman et al., 1994) and improvement of
parkinsonian symptoms with lesions or STN HFS (Aziz et al., 1992;Bergman et al.,
1990).
STN has increasingly become the preferred target for DBS for PD as it has been
found to have a positive effect on a wide range of symptoms. OFF motor symptoms can
show a dramatic improvement of 40%-60% (Limousin and Martinez-Torres, 2008) while
bradykinesia, rigidity, tremor, and axial symptoms also improve (Kleiner-Fisman et al.,
2003;Krack et al., 2003;Schupbach et al., 2005). L-Dopa-induced-dyskinesias also
improve over time, mostly due to a reduction in medication dosage in the range of 30% to
50% (Limousin and Martinez-Torres, 2008).
While the therapeutic benefits of DBS are clear, its mechanism of action remains
debatable. It is unclear whether the therapeutic effects are local or system-wide, or even
whether the effects are related to inhibition or excitation. Several studies have reported
inhibition of neuronal activity locally during HFS in the GPi (Dostrovsky et al., 2000)
24
and STN (Filali et al., 2004) of humans, and GPi in primates (Boraud et al., 1996). Other
studies have examined the effect of HFS on downstream targets, and the findings suggest
an activation of efferent axons either directly or through activation of local cell bodies to
axon initial segments (Anderson et al., 2003;Hashimoto et al., 2003). Recent work has
shown that HFS affects other properties of firing patterns such as oscillatory and burst
activity (Brown et al., 2004;Dorval et al., 2008;Kuhn et al., 2006;Xu et al., 2008)
suggesting that DBS may suppress the proposed pathological patterns of activity in the
basal ganglia.
Presently, there is no surgical alternative to DBS. Dopaminergic cell transplant
and intraputaminal delivery of glial cell line-derived neurotrophic factor have shown
some improvement in a limited patient set, but these procedures have been stopped
because of side effects, such as worsening dyskinesia, and inconsistencies of the
treatment effect (Gill et al., 2003). Other forms of restorative treatment, in particular gene
therapy, are under investigation (Kaplitt et al., 2007). These approaches might someday
replace DBS for many patients.
1.4 Synaptic Plasticity
Neurons connect to one another via synapses, which are the primary site of
information transmission in the nervous system. Information storage, including memory
and behavioural adaptation, is believed to emerge from changes in neuronal transmission,
both over short- and long-term time frames, a property known as synaptic plasticity. The
earliest hypotheses on mechanisms of information storage date back to the late 19th
century, where theorists proposed that increased utilization of circuits either strengthened
25
existing circuits or promoted the formation of new circuits (Tanzi, 1893). Hebb famously
put forward the modern formulation of this theory stating that “when an axon of cell A is
near enough to excite a cell B and repeatedly or persistently takes part in firing it, some
growth process or metabolic change takes place in one or both cells such that A's
efficiency, as one of the cells firing B, is increased” (Hebb, 1949).
We now know that synaptic plasticity takes many forms and occurs in many
regions of the central nervous system. Plastic change can occur and decay rapidly and
involves post-translational modifications of synaptic proteins while being protein-
synthesis independent (Raymond, 2007). Additionally, some forms of plasticity can be
dependent on protein synthesis but independent of gene transcription, while other forms
can be more persistent and depend on both gene transcription and protein synthesis
(Raymond, 2007). It is a highly regulated process emerging from complex interactions
occurring not just at the synapse, but also on a molecular, cellular, and system level.
1.4.1 Long-term potentiation
The central nervous system uses short- and long-term changes in synaptic strength
in neuronal circuits to process large amounts of information. One such change, or
activity-dependent modification, is long term potentiation (LTP). Studied extensively in
the hippocampus, LTP is a sustained increase in synaptic strength that is elicited
following short trains of high frequency or patterned stimulation. LTP has long been
thought to play a crucial role in memory formation and learning as a result of its
properties (rapid generation, input specificity, associativity, and long lasting nature)
26
(Bliss and Lomo, 1973;Nicoll et al., 1988) and the observation that LTP-like activity
occurs in brains of animals learning a behavioural task (Berger, 1984;Moser et al., 1994).
Further evidence for a link between LTP and learning and memory is provided by studies
where pharmacological blockade of LTP disrupts behavioural learning (Davis et al.,
1992).
1.4.1.1 LTP Mechanisms
Classically, activity-dependent LTP occurs at glutamatergic synapses containing
the NMDA receptor. This receptor is permeable to Ca2+, but is blocked by physiological
concentrations of Mg2+. Depolarization expels Mg2+ from the NMDA receptor channel
which in turn allows Na2+ and Ca2+ ions to pass into the postsynaptic cell (Nicoll, 1998).
The Ca2+ ions that enter the cell serve as a second messenger and activate postsynaptic
protein kinases (Nicoll and Malenka, 1999). Through a cascade of events, these kinases
can act postsynaptically to cause insertion of new AMPA receptors into the postsynaptic
spine, thereby increasing the postsynaptic cell’s sensitivity to glutamate (Malenka and
Bear, 2004). These changes occur rapidly, are post-translational in nature, and can last for
hours to days (Malenka and Bear, 2004) (Figure 4).
Ultimately, the changes resulting from the interactions of various signal
transduction pathways can be translated into even longer-term effects by downstream
changes in gene expression. This late phase of LTP is initiated by transcription factors
such as CREB, which mediates gene expression through a Ca2+/cAMP responsive
element (CRE) on target genes (Squire and Kandel, 1999). CREB is continuously
27
expressed but can only bind CRE and influence transcription upon its phosphorylation
(Gonzalez and Montminy, 1989;Montminy and Bilezikjian, 1987;Yamamoto et al.,
1988). Phosphorylation of CREB occurs via multiple pathways; activated PKA can
rapidly phosphorylate CREB (Gonzalez and Montminy, 1989), as can multiple Ca2+
/calmodulin-dependent kinases (CaMKs) (Bito et al., 1996;Dash et al., 1991;Kasahara et
al., 2001). Functionally, by altering gene expression, this late phase LTP can produce
additional transcriptional regulators and even aid new synapse construction (Engert and
Bonhoeffer, 1999) (Figure 4).
28
Figure 4 Mechanisms responsible for long-lasting changes in synaptic transmission during LTP. A) Depolarization removes the Mg2+ block from the NMDA receptor and allows Ca2+ entry. Ca2+ activates postsynaptic protein kinases which, through a cascade of events, can act to insert new AMPA receptor into the postsynaptic terminal. B) The late component of LTP alters gene expression. PKA or CaMKs phosphorylate and activate CREB, a transcriptional regulator, which can turn on specific genes that can alter synapse structure and affect the activity of various transcriptional regulators. (Adapted from Squire and Kandel, 1999)
In addition to postsynaptic changes, presynaptic changes can cause increased or
decreased synaptic activity. By altering the release properties of vesicles carrying
neurotransmitter, the synapse has an additional site and mechanism for regulation. Best
understood in the gill withdrawal response of Aplysia, presynaptic facilitation can
produce enhanced synaptic activity independent of the postsynaptic LTP response
discussed above. A tail shock activates sensory neurons which in turn excite serotonergic
29
interneurons (Abrams, 1985). Serotonin release activates adenyl cyclase and produces
cAMP (Abrams, 1985). cAMP then activates PKA which phosphorylates key targets
involved with exocytosis, such as P/Q-type voltage-activated Ca2+ channels (to enhance
Ca2+ influx), synapsins (to enhance vesicle trafficking), and soluble N-ethylmaleimide
attachment protein receptor (SNARE) (to enhance vesicle docking, priming, and fusion)
(Arias-Montano et al., 2007). As in the general LTP mechanism discussed above,
prolonged serotonergic stimulation and subsequent PKA activation can result in changes
in gene expression during presynaptic facilitation (Pittenger and Kandel, 2003). PKA
activates CREB, and it can also activate another kinase, p42 MAPK (Martin et al., 1997).
Both CREB and p42 MAPK can move to the nucleus of the presynaptic cell and bind /
phosphorylate key targets which have various downstream effects, including alterations
of PKA activity and synapse growth.
Another cAMP-dependent presynaptic form of LTP has been described in the
hippocampus at mossy fiber synapses, the junction between the axons of dentate gyrus
granule cells and the proximal apical dendrites of CA3 pyramidal cells. Similar to the gill
withdrawal response in Aplysia, mossy fiber LTP involves a PKA-dependent, long-
lasting modification of the presynaptic release machinery, ultimately causing an
increased probability of transmitter release as well as the recruitment of new or
previously silent release sites (Reid et al., 2004;Tong et al., 1996). This form of LTP does
not require the activation of NMDARs. Rather, it relies on an activity dependent rise in
intracellular calcium concentration in presynaptic terminals and it appears that activation
of presynaptic kainate receptors by endogenous glutamate plays a role in facilitating
mossy fiber LTP (Contractor et al., 2001;Lauri et al., 2003;Schmitz et al., 2003).
30
1.4.2 Long-term Depression
For changes in synaptic plasticity to be useful, processes other than LTP must
exist that serve to selectively weaken synapses. Long-term depression (LTD) has been
described as one such way to decrease synaptic strength. Like LTP, LTD has been
studied extensively in the CA1 region of the hippocampus. Much study has also focused
on LTD at Purkinje cells of the cerebellum. While the LTD mechanisms are not simply
the mechanistic reversal of LTP, the net effect at excitatory synapses is the internalization
of AMPA receptors on the postsynaptic membrane, thereby decreasing the postsynaptic
cell’s sensitivity to glutamate (Malinow and Malenka, 2002). Although some collective
processes exist, molecular, biochemical, electrophysiological and pharmacological
studies all point to several distinct induction and maintenance mechanisms for this form
of synaptic plasticity (Braunewell and Manahan-Vaughan, 2001).
1.4.2.1 LTD Mechanisms
LTD is best understood in terms of two mechanism; LTD triggered by NMDAR
activation, and LTD triggered by mGluR activation. Whereas NMDAR dependent LTP in
the CA1 region requires brief high frequency stimulation, NMDAR dependent LTD in
this region is induced by much longer trains (>900 stimuli) of low frequency stimulation
(0.5-5 Hz) (Malenka and Bear, 2004). Inhibition of NMDARs blocks LTD (Dudek and
Bear, 1992), and activation of NMDARs induces it (Cummings et al., 1996;Kandler et
al., 1998;Li et al., 2004). As mentioned above in the LTP discussion, NMDARs allow
31
Ca2+ entry in to the cell. Furthermore, intracellular uncaging of Ca2+ via photolysis is
sufficient to induce LTD (Yang et al., 1999). Therefore, Ca2+ entering the postsynaptic
cell through the NMDAR as a trigger for LTD emerged as a model. Like LTP, however,
the quantitative characteristics of the postsynaptic Ca2+ signal required to trigger LTD
remain to be determined (Malenka and Bear, 2004). Once inside the postsynaptic cell,
Ca2+ activates protein phosphatases. These phosphatases act to dephosphorylate key
targets, including PKC and PKA substrates (Hrabetova and Sacktor, 2001;Kameyama et
al., 1998;van Dam et al., 2002) and AMPARs (Lee et al., 1998;Lee et al., 2000). This
dephosphorylation ultimately leads to either lower AMPAR channel opening probability
(Banke et al., 2000) or rapid internalization of AMPARs (Banke et al., 2000;Beattie et al.,
2000;Carroll et al., 1999;Lee et al., 2002).
Mechanistically distinct forms of mGluR-dependent LTD are also found in the
CA1 region of the hippocampus (Oliet et al., 1997), as well as in Purkinje cells of the
cerebellum (Ito et al., 1982). In these cases, glutamate binds and activates mGluRs on the
postsynaptic membrane, a G-protein coupled receptor capable of inducing signal
transduction cascades. mGluR activation produces several second messengers which in
turn activate PKC. PKC then phosphorylates key substrates on certain AMPA receptors
leading to endocytosis of AMPA receptors comprised of the subunits GluR2 and GluR3
(Chung et al., 2003;Wang and Linden, 2000).
A presynaptically expressed form of mGluR-dependent LTP has also been
described in the hippocampus. Treatment with the mGluR agonist DHPG [(RS)-3,5-
dihydroxyphenylglycine] causes a long-lasting increase in paired-pulse ratios (paired
pulse facilitation) and decrease in the success rate of dendritically recorded EPSCs
32
without affecting their potency (Fitzjohn et al., 2001). The phenomena of paired-pulse
facilitation and depression are well known forms of synaptic plasticity. They are
expressed in electrophysiological experiments as changes in the amplitude of a test EPSC
evoked by a second presynaptic spike that follows the first (conditioning) one in the
paired-pulse paradigm (Zucker and Regehr, 2002).
Further experiments found that presynaptic vesicle release was reduced under
these conditions (Zakharenko et al., 2002), while the postsynaptic sensitivity to AMPA
and glutamate remained unaltered (Rammes et al., 2003;Tan et al., 2003).
1.4.3 GABAergic Plasticity
Like excitatory connections, many recent studies have indicated that activity-
dependent forms of synaptic plasticity, such as LTP and LTD, can play a role in the
establishment and regulation of functional inhibitory synaptic connections (Gaiarsa,
2004). As described above, long term changes in the strength of synaptic efficacy at
excitatory synapses can be accounted for by at least three non exclusive mechanisms: i)
modifications in the probability of transmitter release, ii) modifications in the number or
properties of receptors at functional synapses, and iii) modifications in the number of
functional synapses through either pre- or post-synaptic mechanisms as a result of
changes in gene expression. Of these mechanisms, the first two have also been
characterized at inhibitory GABAergic synapses and will be covered below.
Changes in the probability of transmitter release have been reported at
GABAergic synapses (Caillard et al., 1999a;Caillard et al., 1999b), with modifications
33
occurring in the number of functional releasing sites. One study showed that ~30% of
postsynaptic GABAA receptors are associated with non-functional presynaptic terminals
in hippocampal cultures (Kannenberg et al., 1999), suggesting the existence of
presynaptically silent GABAergic synapses. Such a scenario might indicate a presynaptic
mechanism of switching on or off neurotransmitter release (Gaiarsa et al., 2002).
Changes in the properties of receptors via alterations in postsynaptic intracellular
Ca2+ levels (and subsequent signal transduction cascades) have also been reported at
GABAergic synapses (Gaiarsa et al., 2002). In the CA1 region of the adult hippocampus,
HFS induces NMDA-dependent LTP of GABAergic synapses (Wang and Stelzer, 1996).
The suggested mechanism involves an increase in the efficacy of postsynaptic GABAA
receptors, induced by activation of the Ca2+-sensitive phosphatase calcineurin (Lu et al.,
2000).
Similarly, changes in the number of available GABA receptors have been shown
to affect the synaptic efficacy at inhibitory synapses. In an experimental model of
temporal lobe epilepsy, a direct relationship between the number of synaptic GABAA
receptors and the quantal size at potentiated GABAergic synapses has been found in the
adult dentate gyrus (Nusser et al., 1998). Insertion of new GABAA receptors is thought to
underlie the increase in amplitude of IPSCs. Additional evidence of this mechanism
occurring at GABAergic synapses comes from cultured hippocampal cells. Blocking
clathrin-dependent endocytosis of GABAA receptors in these cells causes a large increase
in quantal size (Kittler et al., 2000).
In summary, several mechanisms for the induction and maintenance of long-term
plasticity have been reported at inhibitory synapses in different brain regions. Not
34
surprisingly, all of these forms of plasticity, like their excitatory counterparts, are
triggered by changes in intracellular Ca2+ concentrations.
1.4.4 Synaptic Plasticity in the Basal Ganglia
While the hippocampus has long been the focus of plasticity studies, many other
brain regions have been shown to undergo plastic changes, including the basal ganglia.
To this point, the majority of work on synaptic plasticity in the basal ganglia has been
directed at the glutamatergic corticostriatal synapse, primarily because of the positioning
of the striatum as a major input structure of the basal ganglia. Notably, this synapse is
also under the neuromodulatory control of dopamine. Resultantly, much work has been
focused on the hypothesis that dopamine plays a key role in long-lasting changes in
neural responses occurring in this region (see review by (Wickens, 2009)).
Indeed, evidence from the Calabresi laboratory strongly supports a role of
synaptic plasticity in PD pathology and/or symptomatology, brought about by changes in
striatal dopamine levels as a result of the disease’s progression. This group reported that
corticostriatal LTD could not be induced in slices prepared from 6-OHDA dopamine-
depleted rats, but could be restored by bath application of exogenous dopamine, or co-
application of both D1 and D2 receptor agonists (Calabresi et al., 1992;Calabresi et al.,
1994). Furthermore, LTD could be prevented from occurring at the corticostriatal
synapse in normal slices by pretreatment with either D1 or D2 antagonists (Calabresi et
al., 1992;Calabresi et al., 1994). These long-lasting reductions in synaptic strength are
thought to be initiated postsynaptically but expressed presynaptically via a 2nd messenger,
35
here an endocannabinoid that travels from the postsynaptic cell and activates presynaptic
CB1 receptors (Kreitzer and Malenka, 2008).
The basic model that has emerged is that HFS in or near the dorsolateral striatum
stimulates both glutamatergic and dopaminergic fibers while also activating L-type Ca2+
channels. HFS-induced elevations of glutamate activate postsynaptic mGluRs, while
increases in dopamine activate D2 receptors. Activation of mGluRs and L-type Ca2+
channels leads to endocannabinoid production and release (Hashimotodani et al., 2005)
while D2 receptor activation serves to enhance the production of endocannabinoids
(Giuffrida et al., 1999). Endocannabinoids are then released from striatal MSNs and
activate CB1 receptors of the excitatory presynaptic cell leading to the induction of
presynaptic inhibition of neurotransmitter release and LTD (Ronesi et al., 2004).
A study using intrastriatal microstimulation obtained results that indicated HFS
could induce robust LTD at indirect-pathway MSNs, but not at direct-pathway MSNs
(Kreitzer and Malenka, 2007). Further, the same study found that direct activation of
mGluRs gave rise to an endocannabinoid-mediated inhibition in indirect pathway but not
direct pathway MSNs, suggesting that indirect-pathway MSNs more readily release
endocannabinoids. Furthermore, the study found that LTD at this synapse is not induced
by depolarization or application of mGluR agonist alone. However, application of a
mGluR agonist in the presence of a D2 agonist is sufficient to induce LTD (Kreitzer and
Malenka, 2007). Thus, dopamine mediates a form of long-lasting inhibition at indirect-
pathway synapses, consistent with i) dopamine as an inhibitor of indirect-pathway
function (Albin et al., 1989), and ii) dopamine as a signal that gates synaptic plasticity
(Schultz, 2002).
36
In contrast, LTD at direct-pathway MSNs can be blocked by increased dopamine
(Shen et al., 2008), consistent with its role in potentiation of direct-pathway function
(Albin et al., 1989). In accordance with such potentiation, it has also been shown that
Dopamine D1 receptors are involved in striatal LTP (Calabresi et al., 2000), while
dopamine depletion has been shown to block striatal LTP (Centonze et al., 1999).
Whereas D1 and D2 receptors appear to act synergistically to enable LTD, they seem to
operate in opposition during induction of LTP (Centonze et al., 1999); corticostriatal LTP
is blocked by D1 receptor antagonists (Kerr and Wickens, 2001) and lost in mice lacking
the D1 receptor (Centonze et al., 2003), whereas LTP can be blocked using a D2 receptor
agonist and enhanced using a D2 receptor antagonist (Calabresi et al., 1997).
As mentioned above, since PD is primarily characterized by the degeneration of
nigral dopaminergic projections to the striatum, much work has focused on characterizing
the changes induced on striatal neuronal plasticity caused by such disruptions. Notably,
corticostriatal LTP is lost in nigral lesioned 6-OHDA rats but can be restored by chronic
(Picconi et al., 2003) or long-term low-dose (Picconi et al., 2008) L-Dopa treatment. L-
Dopa has long been on the frontline of treatment for PD sufferers, but an unfortunate
consequence of its use is the development of dyskinesias, severe involuntary movements,
in the vast majority of these patients (Obeso et al., 2000a). Interestingly, after the
induction of LTP at corticostriatal synapses, LFS can depotentiate LTP. This
depotentiation is selectively lost in rats that developed a dyskinetic response to L-Dopa
treatment (Picconi et al., 2003;Picconi et al., 2008). Hence, it is conceivable that
pharmacological modulation of corticostriatal synaptic plasticity might prove useful in
the treatment of motor symptoms observed in PD (Picconi et al., 2005).
37
1.4.5 Measuring Plasticity in Human Subjects
To this point, one experimental paradigm, paired associative stimulation (PAS),
has proven successful in inducing LTP-like changes in human subjects. Developed by
Stefan, PAS measures changes in motor cortex excitability by using low-frequency
median nerve stimulation paired with transcranial magnetic stimulation of the
sensorimotor system of the motor cortex (Stefan et al., 2000). LFS with an interstimulus
interval of at 10 ms decreases motor cortex excitability while at intervals above 25 ms
enhances motor cortex excitability (Wolters et al., 2003). These changes in excitability
are long lasting, region specific, and are blocked by NMDAR or L-type voltage-gated
channel antagonist (Stefan et al., 2002).
This same protocol has been used to demonstrate that PD patients, both dyskinetic
and non-dyskinetic alike, have deficient LTP-like effects in the human motor cortex
(Morgante et al., 2006). Interestingly, this study also found that treatment with L-Dopa
restores potentiation of motor evoked potentials in non-dyskinetic patients but not in
dyskinetic patients. Such results further indicate that PD is associated with aberrant
plasticity and that changes in dopamine levels are intricately tied to changes in plasticity.
38
1.4.6 LTP and LTD as Models for Behaviour
It should be noted that both LTP and LTD are experimental phenomena which are
used to demonstrate the repertoire of long-lasting changes of which individual synapses
are capable. It has been near impossible for researchers to demonstrate identical synaptic
modifications due to the same mechanisms underlying some form of LTP or LTD
occurring in vivo in response to experience (Malenka and Bear, 2004). However, given
the ubiquity of the assorted forms of LTP and LTD at both excitatory and inhibitory
synapses throughout the brain, and the computational advantage they afford, it seems
certain that the brain takes advantage of its circuits’ capability to express long-lasting
activity-dependent modifications as at least one of the fundamental mechanisms by which
experiences modify neuronal behaviour.
39
2 OBJECTIVE & HYPOTHESIS
2.1 Objectives
The progressive loss of SNc neurons that characterizes PD pathology leads to
impaired levels of dopamine at the basal ganglia input. However, as touched on in the
opening paragraphs of the Introduction, the SNc also sends ventrally projecting dendrites
to the SNr (Cheramy et al., 1981;Geffen et al., 1976;Korf et al., 1976;Robertson et al.,
1991), and little is known of the effects of dopamine released from these ventral SNc
projections. Alterations in dopamine levels have been shown to be coupled to changes in
synaptic plasticity at the corticostriatal synapse; this study set out to determine if similar
processes were ongoing at basal ganglia output structures, specifically, the extent to
which dopamine modulates synaptic plasticity in the SNr.
During the course of initial intra-operative mapping sessions it was determined
that stimulation in the SNr evoked a positive extracellular field potential in SNr. Since
the SNr receives projections from a variety a structures, both excitatory and inhibitory, it
became clear that determining the nature of this extracellular field would be important,
since it would be alterations in this field’s amplitude which would tell us something about
the plastic properties of basal ganglia output neurons.
To summarize, the two objectives of this study were: i) to determine the nature of
the positive field evoked potential (fEP) we observe in substantia nigra pars reticulata
(SNr) recordings, and ii) to determine the relationship between dopamine and synaptic
plasticity by measuring changes in fEP amplitude following stimulation in PD patients
ON and OFF dopaminergic medication.
40
2.2 Hypotheses
1 The positive field (fEP) we observe in our recordings of basal ganglia output
neurons is a GABA-mediated field IPSP.
2 Dopamine enhances synaptic plasticity in basal ganglia output neurons.
41
3 METHODS
3.1 Patients
Using intraoperative microelectrode recordings, we studied 18 patients undergoing
stereotactic surgery for implantation of bilateral STN-DBS electrodes. Patients undergo
STN DBS surgery for the treatment of the cardinal signs of PD: akinesia and
bradykinesia, rigidity and tremor. PD patients are selected for surgery based on clinical
evaluations of each patient’s response to levodopa and the degree to which they suffer
from levodopa-induced dyskinesias (Lang and Lozano, 1998a). The clinical
characteristics of the patients and their daily doses of anti-PD medications are shown in
Table 1. The group, consisting of 14 men and 4 women, had a mean age (± SD) of 58.9 ±
6.8 years and mean disease duration (± SD) of 13.3 ± 4.4 years. Six patients were most
affected on their right side, while nine patients were most affected on their left side.
Three patients were severely affected bilaterally. Patients normally underwent a
minimum of 12 hours of anti-PD medication withdrawal before microelectrode mapping
for DBS implantation, and were awake with local anesthesia for measures of synaptic
plasticity in SNr following completion of the electrophysiological mapping of the STN.
The UPDRS III ON and OFF motor scores given in Table 1 were obtained during patient
work-up for DBS and were taken at an earlier time point. The OFF measures were taken
following 12 hours of anti-PD medication withdrawal while the ON measures were
performed following a dose 20% greater than patients’ normal morning dose. The normal
morning dose is typically 15-25% of the daily dose. Six patients were studied first in the
“OFF” state following 12 hour withdrawal and then in the “ON” state after oral
42
administration of 100 mg of levodopa (Sinemet 100/25®) in the contralateral
hemisphere. An additional 6 patients were studied only in the OFF state in order to avoid
the occurrence of severe dyskinesia during surgery. In 4 cases the patient was given one
tablet of Sinemet 100/25® immediately before the procedure as it was deemed medically
necessary for the patient (Patients 4, 6, 8, and 9 in Table 1). UPDRS motor scores
indicate that all patients had some degree of motor improvement when ON L-Dopa with
an average improvement (± SD) of 61.5 ± 13.0 % in the ON state. The experiments were
approved by the University Health Network and University of Toronto Research Ethics
Boards. Patients provided written informed consent prior to the procedure.
43
Table 1 Patient Characteristics
Case Age/Sex/ Worst Side
Disease duration (years)
Medication (Daily Dose)
L-DOPA equivalence
(mg/day)
UPDRS III (OFF/ON)
% Imprv Tests
1 61/M/L 16 L-DOPA 800mg, Pramipexole 2mg,
Amantadine 200mg 1000 40 / 20.5 49 OFF & ON
2 68/M/R 21 L-DOPA 1100mg,
Pergolide 2mg, Selegiline 10mg
1300 31.5 / 13 59 OFF
3 65/M/R 7 L-DOPA 675mg, Pramipexole 2mg 875 48 / 19 60 OFF & ON
4 63/M/L 11 L-DOPA 1400mg,
Amantadine 100mg, Cabergoline 2mg
1500 46 / 16.5 64 ON (2)
5 57/M/L 10 L-DOPA 1500mg 1500 33 / 6 82 OFF 6 54/F/L 10 L-DOPA 300mg,
Ropinirole 16mg 566.66 41 / 18 56 ON 7 57/F/B 9 L-DOPA 1450mg 1450 48 / 18.5 61 OFF
8 70/F/L 15 L-DOPA 412.5mg, Amantidine 100mg, Pramipexole 3mg
712.5 43.5 / 20.5 53 ON (2)
9 66/F/B 15 L-DOPA 1150mg Ropinirole 15mg 1400 40 / 13 67 ON
10 56/M/L 24 L-DOPA 1150mg Tolcapone 300mg Amantidine 200mg
1500 44 / 17.5 60 OFF
11 61/M/L 11 L-DOPA 1100mg 1100 40 / 10 75 OFF (2) 12 58/M/B 13 L-DOPA 1600mg
Entacapone 800mg 1920 32.5 / 24 26 OFF & ON
13 62/M/R 13 L-DOPA 825mg Pramipexole 2.25mg 1150 28.5 / 10 65 OFF
14 54/M/L 17 L-DOPA 650mg
Entacapone 800mg Ropinirole 20mg
1300 19.5 / 7.5 62 OFF & ON
15 62/M/R 9 L-DOPA 1950mg Amantidine 200mg 1950 27.5 / 4.5 84 OFF & ON
16 46/M/R 10 L-DOPA 1450mg Entacapone 200mg 1530 NA NA OFF & ON
17 57/M/L 15 L-DOPA 1600mg Entacapone 800mg 1920 48 / 20.5 57 ON *
18 44/M/R 14 L-DOPA 500mg
Pramipexole 2.25mg Amantidine 300mg
825 52.5 / 18.5 65 ON **
Mean 58.9 ± 6.8 13.3 ± 4.4
===========
1301 ± 409 39.0 ± 8.9 /
15.1 ± 5.5 61.5 ± 13.0
44
3.2 Surgery
The surgical procedure for stereotactic, microelectrode-guided STN localization
and placement of DBS electrodes (Medtronic Model 3387, Minneapolis, MN) for PD has
been described elsewhere in detail (Hutchison et al., 1998) and will be reviewed briefly
here. Patients’ antiparkinson medications are withheld a minimum of 12 hours before the
surgery. A stereotactic frame is affixed to the patient’s head after local anesthetic is
applied. Pre-operative MR images are obtained and axial images are used to determine
the x-, y- and z co-ordinates of the anterior and posterior commissures with respect to the
stereotactic frame. The pre-operative target is chosen to be the ventral border of STN.
Coordinates of the tentative target are 12 mm lateral to the midline, 2 to 4 mm posterior
to the mid-commissural point and 3 mm below the AC-PC line (Hutchison and Lozano,
2000). Patients lie in a supine position on the operating room table and 5 cm incisions are
made 3 cm lateral to the midline. Burr holes are then drilled at the coronal suture and the
underlying dura mater is opened to allow the microelectrodes access to the brain. Surgical
fibrin glue (Tisseel, Baxter) is used to cover the dural opening and prevent cerebrospinal
fluid loss during the surgery. A Leksell arc is attached to the head frame and set to the
coordinates of the target. A cannula is inserted into the brain to a depth of 10 mm above
target and the inner stylet is removed. Two microelectrodes, enclosed in individual steel
guide tubes and spaced 600 to 800 μm apart, are then inserted into the cannula and driven
by submillimeter increments into the brain by independent manual hydraulic microdrives.
45
3.3 Intraoperative Microelectrode Field Evoked Potentials & Neuronal Recordings
Dual gold and platinum plated parylene-C insulated tungsten microelectrodes
were used during surgery. Microelectrode tip length was approximately 25 μm and
impedances ranged from 0.2-0.4 MΩ at 1000 Hz. As mentioned above and shown in
Figure 5, microelectrodes were spaced 600-800 μm apart and were driven by
submillimeter increments through a steel tube guide tube into the brain by independent
manual hydraulic microdrives (Figure 5). Recordings were amplified 5,000-10,000 times
and filtered at 10 to 5,000 Hz (analog Butterworth filters: high-pass, one pole; low-pass,
two poles) using two Guideline System GS3000 amplifiers (Axon Instruments, Union
City, CA). Microelectrode data were sampled and digitized at 12 kHz with a CED 1401
(Cambridge Electronic Design [CED], Cambridge, UK) and EMG of ipsi- and
contralateral wrist and foot flexor and extensor muscles was sampled at 500 Hz to
monitor any dyskinetic movements.
Neuronal activity was continuously recorded along linear tracks from ventral
thalamus, through zona incerta and STN, to dorsal SNr (example traces are shown in
Figure 6a). Target nuclei were localized via characteristic neuronal discharge patterns
described elsewhere in detail (Hutchison et al., 1998). Briefly, after passing through
thalamus, typically consisting of bursting cells, and the quieter zona incerta, entry into
STN was marked by an increase in background activity and large amplitude, irregularly
firing spikes. Exit from STN was noted by a decrease in noticeable background activity.
If the length of the track within STN was longer than 5 mm the track was considered to
run through the middle of the STN and was sufficient for a site of implantation.
46
Otherwise, further tracks were recorded until the middle of the nucleus was found. The
SNr was identified by the presence of neurons with a significantly higher discharge rate
and more regular firing pattern (vs. STN). The SNr neurons also displayed
characteristically low thresholds (2–4 uA) for microstimulation-induced inhibition of
firing (Dostrovsky et al., 2000;Lafreniere-Roula et al., 2009). An example of a typical
trajectory is shown in Figure 8. All recording sites were deemed to be near the region of
the soma and the spike amplitude was continuously monitored in order to confirm
stability of electrode position.
Since the primary goal of the microelectrode recordings was to confirm the
location of STN, in order to improve clinical benefit to PD patients from DBS
implantation, the number of SNr recording sites that could be tested for plasticity
responses per patient and the length of time spent at each recording site was limited by
the clinical aim of the surgery.
47
Figure 5 Microelectrode Apparatus. Schematic of the two microelectrodes that are inserted into the brain of patients with PD during DBS surgery (A). Each microelectrode is encased in its own guide tube (B), allowing for independent manipulation of microelectrode depth (C). Microelectrodes are separated by approximately 600 um. One microelectrode can be replaced with a macroelectrode (bottom C) for stimulation purposes. (modified from Levy et al J Neurosurg 60: 277, 2007)
A B C
48
Figure 6 Example of neuronal traces. A) Raw traces showing examples of typical cell firing found in different basal ganglia structures. Top trace shows a thalamic bursting cell. Each burst typically contains two to six spikes in quick succession. Bursts can occur at various intervals but typically occur between 3-6 Hz during recordings. The 2nd trace shows an STN cell. This cell fires fast (20-40 Hz) and slightly irregular. Third trace shows a SNr cell. This cell fires very fast (typically > 50Hz) and in a highly regular manner. Adapted from (Hutchison et al., 1998). B) An example of an SNr cell recorded during stimulation at 1 Hz from the 2nd electrode (B, top trace). The stimulas artefact (3 large vertical lines) is visible, as are the fEPs (arrow). The bottom plot is an example of wavemark data. The spikes were extracted from the raw recording and assigned to a template corresponding to the shape of the action potential. All of the spikes in this example were classified as belonging to a single template.
Example of SNr with fEPs
Wavemark of Spike from above example
Thalamic Bursting Cell
STN
Snr
B
A
49
3.4 Stimulation
fEPs were recorded from one electrode while stimulating with single pulses (100
uA, 0.3 ms biphasic pulse width) from a second electrode separated mediolaterally by 0.5
– 1.0 mm at the same dorsoventral level within the SNr. Depth profiles were examined in
some cases by moving the stimulating electrode in 250 um increments above and below
the recording site for up to a 3 mm separation. Paired pulse response (PPR) curves were
constructed in 6 patients using a variety of paired pulse interstimulus intervals (20, 30,
50, 100, & 200ms) by comparing the ratio of the peak amplitude of the 2nd fEP to the 1st
fEP.
After obtaining a stable baseline of peak fEP amplitudes at 1 Hz, high frequency
stimulation (HFS) was given, consisting of four 100 Hz trains, 2 seconds in length,
repeated 4 times every 10 seconds (100 uA, 0.3ms pulse width). Blocks of 10 pulses were
tested every 30 sec for at least 2 minutes, or until a stable plateau had occurred.
Plasticity was quantified using fEP amplitudes in both OFF and ON dopaminergic
medication states, with the first side being done after 12 hours off medication and the
second side following administration of Sinemet 100/25®. Typically, 25 to 30 minutes
had elapsed between the time of administration (Sinemet 100/25® was given as
recording began on the “ON” track) and SNr testing. The sites where synaptic plasticity
was tested are shown in Figure 8 and were determined by track reconstruction using
neurophysiological landmarks and a customized brain atlas-based program.
50
10s
Bas
elin
e (X
2)
Pos
t-HFS
stim
uli
(test
ed e
very
30s
im
med
iate
ly
follo
win
g H
FS)
Hig
h Fr
eque
ncy
Stim
ulat
ion
Stan
dard
Hig
h Fr
eque
ncy
Stim
ulat
ion
Prot
ocol
(HFS
)
30s
2s10
s
Bas
elin
e (X
2)
Pos
t-HFS
stim
uli
(test
ed e
very
30s
im
med
iate
ly
follo
win
g H
FS)
Hig
h Fr
eque
ncy
Stim
ulat
ion
Stan
dard
Hig
h Fr
eque
ncy
Stim
ulat
ion
Prot
ocol
(HFS
)
30s
2s10
s10
s
Bas
elin
e (X
2)B
asel
ine
(X2)
Pos
t-HFS
stim
uli
(test
ed e
very
30s
im
med
iate
ly
follo
win
g H
FS)
Hig
h Fr
eque
ncy
Stim
ulat
ion
Hig
h Fr
eque
ncy
Stim
ulat
ion
Stan
dard
Hig
h Fr
eque
ncy
Stim
ulat
ion
Prot
ocol
(HFS
)
30s
30s
2s2s
Figu
re 7
HFS
Stim
ulat
ion
Prot
ocol
. Bas
elin
e st
imul
atio
n co
nsis
ts o
f 10
sec
onds
of
1 H
z st
imul
atio
n re
peat
ed tw
ice.
Hig
h fr
eque
ncy
stim
ulat
ion
is th
en a
pplie
d. 2
sec
onds
of 1
00 H
z st
imul
atio
n is
app
lied
and
repe
ated
eve
ry 1
0 se
cond
s a
tota
l of 4
tim
es. F
ollo
win
g H
FS, 1
0 se
cond
trai
ns o
f 1 H
z st
imul
atio
n ar
e re
sum
ed a
nd re
peat
ed e
very
30
seco
nds
for a
t lea
st 2
m
inut
es to
test
for a
cha
nge
in fE
P am
plitu
de.
51
3.5 Analysis of Neuronal Activity
Neuronal recordings were analyzed offline using Spike2 software version 6
(CED, Cambridge, UK). Post stimulus time histograms (PSTHs, 250 us bin width, time
base 150 ms normalized to firing rate in Hz) were constructed of the high frequency
spiking of putative GABAergic output neurons of SNr in 2 patients. PSTHs show the
likelihood of an event (spike) falling at a given period after an event (test pulse) on a
different channel. The histograms simply show the number of events that fell in a
particular time bin. Spike analysis was performed using a spike matching template
algorithm in Spike2 (See Figure 6b for an example of a template with a single type of
spike). Briefly, spikes were extracted from a waveform channel and assigned to a
template corresponding to the shape (amplitude, slope, latency, etc.) of a given spike.
For PSTHs, only those spikes identified as belonging to a single template were included,
i.e. a single unit was used for analysis.
fEP amplitudes were evaluated using the monophasic W_FP script in Spike 2.
This script detects the amplitude and latency of peaks in the neuronal recordings at user
defined events. Here, the beginning of the 1 Hz stimulation artefact was used as the
“event” . These measurements were then normalized to a percent scale, with the average
of baseline measures in each patient considered as 100%, and sorted by medication state
(OFF vs ON). Synaptic potentiation was evaluated in each patient in all medication states
by fitting an exponential function to the fEP amplitudes using Sigma Plot software
(SPSS, Chicago, USA): y = yo + ae-bx where yo is the plateau value (relative to baseline
fEP amplitude) to which the function decays, a is the difference of the maximum (first)
52
value of the exponential curve to yo, and b describes the steepness of the curve.
Population data was fit with a regression line if the fit had a significance value of p <
0.05.
3.6 Statistics
All statistical comparisons were conducted using Sigmastat software (Systat
Software Inc., San Jose, USA). A 2-way ANOVA was performed on the normalized data
testing the main effects of DRUG (ON vs OFF) and TIME following HFS. A post-hoc
Bonferroni t-test tested all pairwise comparisons between ON and OFF at each time
point. A p value of 0.05 was taken as significant.
53
4 RESULTS
4.1 fEP Test Sites
All sites tested for a field evoked response were located in the SNr. We tested a
total of 24 SNr sites in 18 patients. The approximate locations of test sites included in the
study are shown in Figure 8. Recordings took place in dorsolateral SNr and test locations
were independent of medication state. fEPs could not be evoked in the STN region using
the stimulation protocols described above.
54
Figure 8 Field Amplitude Test Locations. Composite figure showing the location of sites tested for a field evoked response in the substantia nigra pars reticulata (SNr). Sites tested following application of dopaminergic medication are shown as closed circles. Neurons tested following 12 hours of dopaminergic medication withdrawal are shown as open circles. The locations of sites tested for synaptic plasticity were determined by track reconstruction using neurophysiological landmarks (shown in the example trajectory from a patient in the study; in this case, the mapping was performed while the patient was OFF) found using microelectrode recordings, and a customized brain atlas program. * denotes a SNr site on the trajectory that was included in the OFF sample. Dorsal (D), ventral (V), anterior (A), and posterior (P) axes are labeled. Relative positions of the thalamus (Thal), hypothalamus (Hpth), and subthalamic nucleus (STN) are shown ((Prescott et al., 2009) used with permission from Brain).
Thal
SNr
55
4.2 Field Potential Characteristics
Blocks of 1 Hz test pulses at incrementally increased stimulation distance were
conducted in 2 patients and revealed a positive field persisting for 2.5 mm dorsoventrally
through the SNr with the peak field amplitude having a latency (± SD) of 5.5 ± 0.8 ms
(An example is shown in Figure 9). Post stimulus time histograms of the cell firing were
analyzed in 2 cases and both revealed that the positive peak of the fEP occurred during
inhibition of firing (Figure 10). Additionally, the enhancement of fEP amplitude in the
ON state post HFS was associated with a slower recovery of the spontaneous firing rate
(Figure 10). This effect was examined in more depth in another patient; a large reduction
in firing rate was observed in the ON state at 5 seconds following HFS and an ANOVA
revealed an overall reduction in firing rate that persisted for up to 35 seconds following
HFS in the ON state (p<0.001) (Figure 11). In the same patient in the OFF state, no
significant reduction in firing rate was observed following HFS (p=0.787) (Figure 11).
56
Figure 9 Example of depth profile of fEP in patient #12 SNr while ON medication. Upon entering the SNr, the stimulating electrode is kept in a fixed position while the recording electrode was moved down in 250 um increments. fEPs were recorded at increasing distances from a fixed stimulation point (-1.75 mm along track in this example), and a (+) field persisted for approximately 2.5 mm ventrally through the SNr.
57
Figure 10 Post stimulus time histograms of SNr neuronal firing in Parkinson’s disease (Patient #1). Traces show the average of 10 raw fEPs overlaid on a PSTH of the same time course (150ms). Traces on the top are from a patient in the OFF state, before (left trace) and following (right trace) high frequency stimulation. Traces on the bottom are from the other side on the same patient following administration of one tablet of Sinemet 100/25®. The positive peak of the field evoked potential occurs during inhibition of SNr cell firing in both the OFF and ON states. Notice that lower firing rate is associated with a larger field ((Prescott et al., 2009) used with permission from Brain).
58
Figure 11 Firing Rate of a SNr cell during fEP amplitude measures. (Patient #8). Top traces show firing rate in Hz of SNr cells during fEP amplitude measures, before and after HFS, both ON (red) and OFF (black) L-Dopa in the same patient. Bar graph on bottom depicts the percentage change in firing rate from baseline at each measurement in time. Following HFS there is a reduction in firing rate lasting for ~ 30s with the effect being highly significant in the ON state. Interestingly, baseline firing rates were higher while the patient was ON L-Dopa, although the measures were made at different sites on the left (ON) and right (OFF) side of the brain. * denotes a significant (p<0.001) reduction in firing rate from baseline measures in the ON state.
**
59
4.3 Paired Pulse Response
A paired pulse response curve was constructed for six patients by comparing the
paired pulse ratio before and after high frequency stimulation at a range of interstimulus
intervals. The results have been averaged across patients in Figure 12. Paired pulse
depression is most apparent at short (20 and 30 ms) interstimulus intervals, both before
and after HFS, evidenced by small paired pulse ratios (PPR). Before HFS, the PPRs at 20
and 30 ms intervals were 0.48 ± 0.018 and 0.76 ± 0.014 respectively. Following HFS,
paired pulse depression was similar in magnitude at short interstimulus intervals (20 ms =
0.31 ± 0.11; 30 ms = 0.74 ± 0.19). However, as the interstimulus interval increased, there
was a marked increase in PPR. Before HFS, the PPRs for intervals of 50, 100, and 200
ms were 1.10 ± 0.050, 1.12 ± 0.051, and 1.07 ± 0.072 respectively. Following HFS the
PPRs at the same intervals were 0.88 ± 0.037, 0.94 ± 0.065, and 0.94 ± 0.072. A 2-way
ANOVA revealed a significant decrease in paired pulse ratio following HFS (p=0.015)
and a highly significant reduction in paired pulse ratio both before and after HFS at 20 ms
(p<0.001). Interstimulus intervals causing maximal paired pulse depression (20 and 30
ms) are similar to those when inhibition of SNr firing occurred following single pulses as
shown in Figure 10.
60
Figure 12 Paired Pulse Measures. A) Raw traces of SNr neuronal activity and fEPs during paired pulse measurements following high frequency stimulation (Patient # 18). Traces, from top to bottom, are taken during paired pulse measurements with interstimulus intervals of 100, 50, and 30 ms respectively. Greater paired pulse depression is seen at smaller interstimulus intervals, as denoted by the arrow on the bottom trace. B) Paired Pulse Response Curve. Shown is the paired pulse ratio before and after high frequency stimulation average across six patients at increasing interstimulus intervals (20, 30, 50, 100, and 200ms). A 2-way ANOVA revealed a reduction in PPR following HFS (p=0.015) with a highly significant reduction (denoted by *) in PPR at 20 ms both before and after HFS ((Prescott et al., 2009) used with permission from Brain).
B
A
*
*
61
4.4 DA Modulation of Synaptic Plasticity in the SNr in PD Patients
Effects of HFS (four 2s 100Hz trains) on fEP amplitudes were examined in 13
patients in the OFF state. In these patients (see Table 1 for daily medication use and L-
Dopa equivalence), HFS did not induce a lasting change in fEP amplitude (see example).
A typical example is shown in Figure 13a and c (open circles), where a modest increase
in fEP amplitude returned to baseline by ~ 50 – 100 s. However, in some patients a larger
initial increase in fEP amplitudes was seen in the OFF state, with a subsequent rapid
decay toward baseline (example in Figure 14). In this case, the patient reported that he
was only about 50% of his worst OFF state. We found a close inverse linear relation (r2 =
0.81, p< .001) between the patients’ clinical OFF rating based on UPDRS III motor
subscale (high values indicate worse motor symptoms) and the peak of activity-
dependent synaptic plasticity induced by HFS (Figure 15a open circles). Patients with a
higher UPDRS OFF score underwent less change in fEP amplitudes following HFS. The
population data for the OFF group shown in Figure 15b (open circles) reveals a
significant initial 28.9 ± 4.9 % increase in fEP amplitude following HFS that then
decayed by 100s to baseline. Regression analysis on population data from the OFF group
revealed a yo fEP amplitude plateau value no different than baseline (2.3 ± 3.8 % above
baseline).
62
A B
C
Figure 13 L-DOPA treatment of a Parkinsonian patient (Patient #1) restores plasticity. a) Averaged fEP measures pre (black) and immediately post (grey) HFS (10 sweeps per trace) in a patient in the OFF state. b) Averaged fEP measures pre (black) and immediately post (grey) HFS (10 sweeps per trace) in the same patient following administration of 100mg L-Dopa. Note the large increase above baseline measures in the ON state. c) Open circles are individual fEP peak amplitudes before L-Dopa treatment and closed circles are ~20 minutes following L-Dopa administration. High frequency stimulation (HFS) does not induce a change in fEP amplitude in the SNr of a patient 12 hours removed from L-Dopa treatment. Following administration of L-Dopa, HFS induced an increased fEP amplitude response in the SNr. Note higher plateau reached in the ON L-Dopa state by 2 min post HFS ((Prescott et al., 2009) used with permission from Brain).
63
Figure 14 L-DOPA treatment of a different Parkinsonian patient (Patient # 3) enhances activity-dependent synaptic plasticity in SNr. Open circles are individual fEP peak amplitudes before L-Dopa treatment and closed circles are ~20 minutes following L-Dopa administration. High frequency stimulation (HFS) induces a marked initial increase and subsequent decline to baseline in fEP amplitude in the SNr of a patient 12 hours removed from L-Dopa treatment. Patient self-reported feeling only “50% OFF”. Following administration of L-Dopa, HFS induced an increased and sustained fEP amplitude response in the SNr of this patient.
L-Dopa treatment of PD patients markedly improved motor UPDRS in all patients
preoperatively (Table 1). Note that the total daily L-Dopa equivalences are approximately
10x greater than the dose administered intraoperatively. Following administration of L-
Dopa, the same HFS protocol induced a much larger increase in fEP amplitudes (Fig
13b). Such fEP amplitude increases persisted over several minutes of testing (Figure 13c;
closed circles). There was also a significant correlation between the patients’ clinical ON
rating based on the UPDRS III motor subscale and the maximum value of activity-
dependent synaptic plasticity induced in the ON group (r2 = 0.80, p<0.001) if three
64
outliers are excluded (Figure 15a closed circles – outliers shown in grey – see Discussion
section 5.4).
Effects of HFS on fEP amplitudes were examined in 12 patients in the ON state
(Figure 15b; closed circles). The largest fEP amplitude measures occurred immediately
following the conditioning stimuli (200.3 ± 19.5 % above baseline) with subsequent
measures showing a decrease in fEP amplitude at each time point with an exponential
decay function. Regression analysis on population data from the ON group’s fEP
amplitudes revealed a yo plateau value of 29.3 ± 5.2% above baseline. The regression
function for the OFF and ON groups was highly significant with plateau values at p <
0.001. Additionally, for the ON group, a b value describing the steepness of the curve
was determined to be 0.019 ± 0.0036 (p < 0.05), which corresponds to a half life
(1/0.019) of 52.6 s for the decay function. The OFF group’s b value was slightly higher
at 0.026 ± 0.015 (not significant), corresponding to shorter half life of 38.8 s.
A two-way ANOVA of population data revealed a highly significant difference
between ON and OFF groups (DF=1, f=799, p<0.001) and a significant difference
between time points (DF=5, f=69, p<0.001). It also revealed an interaction between
medication state and time, i.e. the ON / OFF amplitude is also dependent on the time of
measurement (DF=5, f=17, p<0.001).
* *
** *
HFS
Time (s)
-50 0 50 100 150 200
fEP
ampl
itude
(per
cent
age
ofco
ntro
l)
0
50
100
150
200
250
ON (n = 12)
OFF (n = 13)
** * *
r2 = 0.81
UPDRS motor subscore10 20 30 40 50
%ch
ange
inam
plitu
deof
fEP
100
150
200
250
r2 = 0.80
Figure 15 Dopamine Enhances Synaptic Plasticity, Population Data. a) OFF UPDRS III motor subscore (open circles) correlates strongly (r2 = 0.81, p< .001) with degree of activity-dependent synaptic plasticity inducible in patients 12 hours removed from anti-PD medication. ON UPDRS III motor subscore (black closed circles) correlates strongly (r2 = 0.80, p< .001) if three outliers are excluded (grey closed circles). If the three outliers are included, no correlation exists (r2 = 0.02). b) Clear difference between fEP amplitude measures in ON (Red) and OFF (Black) populations following HFS, with the ON group experiencing an increase in amplitude of 29.3% (SEM ± 5.2) above baseline measures following plateau, while the OFF group undergoes a transient increase and subsequent decline back to baseline by 160s. Curves were fit using exponential decay function y = yo + ae-bx, where y0 is the plateau value to which the function decays, a is the difference of the maximum (first) value of the exponential curve to y0, and b describes the steepness of the curve. A two-way ANOVA reveals that the difference in the mean values among between ON and OFF after allowing for effects of differences in TIME is significant (DF=1,f=799,p<0.001). Likewise, the difference in the mean values between time points after allowing for effects of differences in medication state is significant (DF=5, f=69, p< 0.001); the test also reveals an interaction between DOPA state and time i.e. the ON / OFF amplitude also depended on the time point (DF=5,f=17,p<0.001) ((Prescott et al., 2009) used with permission from Brain).
66
5 DISCUSSION
This study describes the characteristics of the positive fEP in the SNr of PD
patients, both OFF and ON dopaminergic medication. It is unique in providing human
data supporting dopamine regulation of synaptic plasticity in the human basal ganglia,
and suggests an important role for activity-dependent synaptic plasticity in basal ganglia
dysfunction.
5.1 Inhibitory Nature of the Field
The SNr receives numerous projections from a multitude of sources, chief among
them the inhibitory GABAergic projection from medium spiny neurons of the striatum
(Bolam et al., 2000;Parent and Hazrati, 1995a;Parent and Hazrati, 1995b). The external
segment of the globus pallidus (GPe) also sends a small, but significant, GABAergic
contribution to the SNr (Smith and Bolam, 1989). Additionally, the STN sends excitatory
projections to the SNr. These glutamatergic projections from the STN to the output
structures of the basal ganglia have been shown to form asymmetric synapses (Ribak et
al., 1981), primarily on the dendrites and shafts, but with a very small number of boutons
terminating on the somata (Kita and Kitai, 1987). The vast majority of the terminals in
the region form symmetric synapses with the somata and are GABAergic in nature
(Ribak et al., 1979;Ribak et al., 1981). The rapid inhibitory responses characteristic of
GABAergic transmission in basal ganglia structures are mediated by the activation of
67
GABAA receptors, which are found exclusively at symmetric synapses (Galvan et al.,
2006).
Based on several observations, our stimulation protocol is primarily activating the
inhibitory GABAergic projections, either from the striatum or the GPe. During our field
recording measurements, all of the field potential measurements in the SNr are positive.
Precht and Yoshida demonstrated the inhibitory nature of a positive field in the SNr by
observing that spontaneous activity of neurons located in the SNr was strongly
suppressed conjointly with the occurrence of the caudate-evoked (GABAergic) positivity
(Precht and Yoshida, 1971;Yoshida and Precht, 1971). They also demonstrated that the
time course of the intracellular IPSP was the same as the positive fEP, and that the
potential was blocked in its entirety by the GABA antagonist picrotoxin. In the present
study, we also saw a positive fEP and its time course was the same as the inhibition of
SNr activity, suggesting that the observed stimulation-evoked positive fEP is associated
with an inhibitory event, most likely local GABA release.
5.2 Dopamine and GABA Release
Our paired pulse studies also point to activation of the GABAergic projections. In
the SNr, dopamine D1 receptors are present at the terminals of the GABAergic
striatonigral projection (Altar and Hauser, 1987;Barone et al., 1987). Previous striatal
studies have shown that paired pulse depression predominates at synapses under the
influence of D1 receptors, whereas paired pulse facilitation predominates at synapses at
which D2 receptors are active (Guzman et al., 2003). In this study, paired pulse
68
depression was evident at short interstimulus intervals prior to HFS and at all
interstimulus intervals following HFS, suggesting that the stimulation evokes effects
involving the presynaptic D1 receptors. Slice studies indicate that stimulation of D1
receptors found in the SNr increases extracellular GABA (Aceves et al., 1991;Aceves et
al., 1995;Floran et al., 1990;Timmerman and Abercrombie, 1996) and that this facilitated
GABA release in turn enhances GABAA IPSCs in nondopaminergic neurons of the SNr
(Radnikow and Misgeld, 1998). Taken together, these observations suggest that our
positive fEP is inhibitory and GABAergic in nature and that dopamine plays a role in
presynaptic regulation of GABA release in this region.
5.3 Dopamine and Plasticity at the Basal Ganglia Output
Dopamine action in the basal ganglia is usually considered in terms of its
modulation (or lack thereof in PD) of indirect and direct striatal output via the
dopaminergic nigrostriatal projection. In this region, dopamine concomitantly provides
excitatory inputs mediated by D1 receptor activation in the direct pathway and inhibitory
inputs mediated by D2 receptor activation in the indirect pathway (Albin et al.,
1989;DeLong, 1990) (Figure 16a). However, dopamine can also have dramatic effects in
other regions of the basal ganglia. Indeed, nigral dopamine depletion has been shown to
impair motor performance independent of striatal dopamine neurotransmission, while
increased nigral dopamine release can counteract striatal dopamine impairments
(Andersson et al., 2006). Here, we posit that dopamine can also act directly in the SNr by
influencing synaptic plasticity at striatonigral synapses (Figure 16c). As previously
69
mentioned, GABAergic and glutamatergic signals converge in the SNr. Based on the
results discussion outlined above, it appears that the field evoked potentials are
GABAergic in nature. In Parkinson’s disease, activity of the GABAergic neurons of the
output nuclei is thought to be enhanced and to cause excessive inhibition of the thalamic
neurons. This inhibition of thalamic activity might thus act as a ‘brake’ on activity of the
supplementary motor cortex resulting in the onset and lasting effects of the parkinsonian
syndrome (Bezard et al., 2001) (Fig. 16b). If this is the case, potentiation of GABAergic
signals onto substantia nigra pars reticulata, by lowering neuronal firing rate, could (at
least in part) mediate the beneficial symptomatic effects of L-Dopa (Figure 16c).
70
Figu
re 1
6Pl
astic
ity a
t Bas
al G
angl
ia O
utpu
t. Th
e im
plic
atio
ns o
f LTP
-like
pl
astic
ity o
f G
AB
Aer
gic
sign
als
onto
SN
r ne
uron
s is
sho
wn.
A)
Dur
ing
phys
iolo
gica
l co
nditi
ons
the
tight
ly r
egul
ated
act
ivity
of
the
dire
ct a
nd
indi
rect
pat
hway
s co
ntro
ls t
he a
ctiv
ity o
f th
e ou
tput
nuc
lei.
B)
Dur
ing
Park
inso
n’s
dise
ase,
in
th
e ab
senc
e of
a
phar
mac
olog
ical
tre
atm
ent,
dopa
min
e de
ficie
ncy
caus
es o
vera
ctiv
ityof
the
ind
irect
pat
hway
and
re
duce
d ac
tivity
of t
he in
hibi
tory
GA
BA
ergi
cdi
rect
pat
hway
, dis
inhi
bitin
gth
e ou
tput
nuc
lei
and
thus
cau
sing
exc
essi
ve i
nhib
ition
of
the
mot
or
thal
amus
. In
this
con
ditio
n, h
igh
freq
uenc
y st
imul
atio
n do
es n
otin
duce
a
last
ing
chan
ge in
the
GA
BA
ergi
cfie
ld p
oten
tial a
mpl
itude
in th
e SN
r. C
) A
fter
the
adm
inis
tratio
n of
L-D
opa,
the
sam
e hi
gh-f
requ
ency
stim
ulat
ion
prot
ocol
indu
ces
pote
ntia
tion
of th
e G
AB
Aer
gic
field
pot
entia
l am
plitu
des,
whi
ch is
ass
ocia
ted
with
a re
duct
ion
of th
e ex
cess
ive
inhi
bito
ryac
tivity
that
th
e ou
tput
nuc
lei
exer
t on
the
mot
or t
hala
mus
. In
hibi
tory
GA
BA
ergi
cco
nnec
tions
are
repr
esen
ted
in re
d, e
xcita
tory
glu
tam
ater
gic
conn
ectio
ns in
gr
een
and
mod
ulat
ory
dopa
min
ergi
c co
nnec
tions
in
blac
k. M
odifi
ed f
rom
C
alab
resi
, 200
9.
CAB Fi
gure
16
Plas
ticity
at B
asal
Gan
glia
Out
put.
The
impl
icat
ions
of L
TP-li
ke
plas
ticity
of
GA
BA
ergi
csi
gnal
s on
to S
Nr
neur
ons
is s
how
n. A
) D
urin
g ph
ysio
logi
cal
cond
ition
s th
e tig
htly
reg
ulat
ed a
ctiv
ity o
f th
e di
rect
and
in
dire
ct p
athw
ays
cont
rols
the
act
ivity
of
the
outp
ut n
ucle
i. B
)D
urin
g Pa
rkin
son’
s di
seas
e,
in
the
abse
nce
of
a ph
arm
acol
ogic
al
treat
men
t, do
pam
ine
defic
ienc
y ca
uses
ove
ract
ivity
of t
he i
ndire
ct p
athw
ay a
nd
redu
ced
activ
ity o
f the
inhi
bito
ry G
AB
Aer
gic
dire
ct p
athw
ay, d
isin
hibi
ting
the
outp
ut n
ucle
i an
d th
us c
ausi
ng e
xces
sive
inh
ibiti
on o
f th
e m
otor
th
alam
us. I
n th
is c
ondi
tion,
hig
h fr
eque
ncy
stim
ulat
ion
does
not
indu
ce a
la
stin
g ch
ange
in th
e G
AB
Aer
gic
field
pot
entia
l am
plitu
de in
the
SNr.
C)
Afte
r th
e ad
min
istra
tion
of L
-Dop
a, t
he s
ame
high
-fre
quen
cy s
timul
atio
n pr
otoc
ol in
duce
s po
tent
iatio
nof
the
GA
BA
ergi
cfie
ld p
oten
tial a
mpl
itude
s, w
hich
is a
ssoc
iate
d w
ith a
redu
ctio
n of
the
exce
ssiv
e in
hibi
tory
activ
ity th
at
the
outp
ut n
ucle
i ex
ert
on t
he m
otor
tha
lam
us.
Inhi
bito
ry G
AB
Aer
gic
conn
ectio
ns a
re re
pres
ente
d in
red,
exc
itato
ry g
luta
mat
ergi
cco
nnec
tions
in
gree
n an
d m
odul
ator
ydo
pam
iner
gic
conn
ectio
ns i
n bl
ack.
Mod
ified
fro
m
Cal
abre
si, 2
009.
CAB
CAB
71
5.4 Plasticity and Motor Behaviour
Previous studies have suggested a link between LTP and dopamine at the
corticostriatal synapse. Indeed, LTP is absent in dopamine lesioned (6-OHDA) rats, but
can be restored with chronic L-Dopa treatment (Picconi et al., 2003). Here, we sought to
characterize activity-dependent synaptic plasticity in basal ganglia output neurons in 18
PD patients, all of whom experienced a significant improvement in motor function during
their preoperatively measured ON state (Table 1). HFS did not induce a lasting change in
fEP amplitude in patients in the OFF state (Figure 16b). However, there was a strong
correlation between the patients’ clinical OFF rating based on the UPDRS (high values
indicate worse motor symptoms) and the initial degree of activity-dependent synaptic
plasticity that could be induced in the same 12 hour defined OFF state. Although the
long-duration response to L-Dopa (Nutt et al., 1995) and the variable half-life of some
dopamine agonists (Rinne et al., 1997) could have interfered with the severity of the OFF
state, 12 hours of anti-PD medication withdrawal induced a noticeable increase in
UPDRS III motor scores in the patients included in this study, and all measures of fEP
amplitudes were done following a similar period of anti-PD medication withdrawal.
Comparatively, during the intraoperative ON state, L-Dopa intake coupled with
HFS caused an increased fEP amplitude response in a manner reminiscent of LTP-like
changes, in addition to decreased SNr firing rates. When including all patients
categorized as being ON, there was no correlation between patients’ clinical ON rating
based on UPDRS III motor subscale and the maximum inducible activity-dependent
72
synaptic plasticity. The lack of correlation in the ON group is likely the result of
variability in intraoperative ON states. As shown in Figure 15b, by excluding three
outliers we see a very strong correlation. Such variability could be derived from a number
of sources including, but not limited to, ineffectiveness of a single dose of L-dopa in
patients taking high doses, the timing of the transient ON period of a single dose, and
when the measurements were performed. For example, the patient whose ON UPDRS
outlier is furthest to left in Figure 15b (UPDRS score 4.5, Patient #15) normally received
1950 mg of L-Dopa equivalence daily. So, for the ON rating measurements done in clinic
(score of 4.5), this patient would have received a dose 20% greater than his normal
morning dose (already 15-25% of daily dose), or approximately 350-575 mg of L-Dopa.
This is much more than the 100 mg received intraoperatively and as such, increases
variability into the ON correlation. Future studies of this nature will attempt to reduce
such variability where possible by matching intraoperative ON doses to those given in
clinic.
5.5 Possible Mechanism for Dopaminergic Modulation of Plasticity in SNr
The rate model predicts that the administration of L-Dopa reduces the elevated
firing rates of basal ganglia output neurons in the OFF state (Hutchison et al., 1997).
Dopamine is thought to have diverse and complex actions on the physiological activity of
the basal ganglia. It can both inhibit and enhance neuronal activity, depending on the
level of membrane depolarization and physiological state of the neuron (Calabresi et al.,
2007). Our observations of lowered SNr firing rates, coupled with enhanced inhibitory
73
synaptic plasticity are consistent with the rate model, and give further hints as to how the
loss of dopamine can directly affect GABAergic striatonigral synapses.
Limitations of the current study prevented the testing of whether dopaminergic
regulation of GABAergic activity was achieved by a pre or postsynaptic mechanism, but
previous work suggests that such actions are likely presynaptic. Enhancement in
miniature inhibitory post synaptic currents (mIPSCs) in the SNr via D1 receptor activity
has previously been shown to be coupled with the formation of cAMP in the pre synaptic
terminal (Jaber et al., 1996). The enhancing effects of D1 receptor stimulation on mIPSC
activity in the SNr can be mimicked by forskolin, which is known to activate adenylate
cyclase (Radnikow and Misgeld, 1998). A more recent study has proposed that D1-
receptor mediated GABA release involves the cAMP/PKA pathway, with PKA
ultimately phosphorylating key targets involved with GABA exocytosis, such as P/Q-
type voltage-activated Ca2+ channels (to enhance Ca2+ influx), synapsins (to enhance
vesicle trafficking), and SNARE proteins (to enhance vesicle docking, priming, and
fusion) (Arias-Montano et al., 2007).
Nevertheless, rapid post synaptic changes in the SNr may also affect GABAergic
activity. Recent work has demonstrated that neuronal activity can directly regulate the
number of cell surface GABAARs by modulating their ubiquitination and consequent
proteosomal degradation in the secretory pathway (Saliba et al., 2007). However, a link
between dopamine and the level of GABAAR insertion and subsequent post synaptic
accumulation has not been established to date, but demonstration of such a link would
support a post-synaptic action of dopamine.
74
Given the evidence from the present study and the earlier studies detailed above
(paired pulse depression, lack of postsynaptic dopamine receptors, no current evidence of
a link between dopamine and GABAAR levels), it appears that the most likely site of
action the dopamine mediated plastic change is presynaptic. However, further basic
studies of the neuropharmacology of synaptic plasticity in SNr slice would be required to
definitively conclude a presynaptic site of action and further elucidate mechanisms.
5.6 Applicability of Findings to the GPi
The work presented here has focused on basal ganglia output neurons in the SNr,
but the other major output structure of the basal ganglia is the GPi, which is the main
projection to the thalamus in the somatomotor loop to cortex. The GPi is anatomically
similar to the SNr in having a major GABAergic input from striatum and minor
glutamatergic input from STN. Like the SNr, it has a relatively homogeneous population
of tonically active GABAergic output neurons. Preliminary work has recorded a similar
positive fEP using single pulse stimulation in the pallidum of patients undergoing the
implantation of DBS in the GPi for dystonia, a movement disorder in which sustained
muscle contractions cause twisting and repetitive movements or abnormal postures. HFS
produces a long lasting enhancement in the amplitude of the fEP in the GPi of dystonia
patients who have never been exposed to chronic L-Dopa therapy. The magnitude of this
enhancement of amplitude is much greater than the plasticity we observed in the OFF
state in the SNr of PD patients indicating that synaptic plasticity is indeed lacking in the
absence of dopamine. In addition, the marked enhancement of plasticity we have
75
reported in the ON state is greater than seen following HFS in the dystonia “quasi-
control” group, suggesting an enhanced plastic response to small doses of L-Dopa in PD
patients exposed to chronic L-Dopa therapy. This may have bearings on mechanisms of
L-Dopa-induced- dyskinesias. A more rigorous investigation of these finding will be
continued in future studies.
76
6 CONCLUSION
The results of this study indicate that synaptic plasticity can be measured in basal
ganglia output neurons of PD patients and that the presence of plasticity is sensitive to
low doses of L-Dopa. This study is unique in being the first of its kind to measure
plasticity at the level of the basal ganglia output neurons in humans. The in vivo nature of
the study provided us with clinically relevant data about the nature of plasticity in
pathological conditions of PD as well as the opportunity to compare quantified
electrophysiological measures in basal ganglia output with actual motor improvements in
patients with PD.
In the absence of dopaminergic medication, plasticity is lacking following HFS.
Conversely, following administration of dopaminergic medication, synaptic plasticity is
facilitated in the SNr by HFS. The close correlation between motor behaviour and the
potential of nigral synapses to undergo activity-dependent changes suggests that
dysfunction of direct dopaminergic action at the basal ganglia output plays an important
role in PD symptomatology.
7 FUTURE STUDIES
As mentioned above, ongoing studies are currently exploring the applicability of
the findings described here to the GPi, the other major output structure of the basal
ganglia. Additionally, one crucial question that arises from the results outlined in this
study and the ongoing GPi studies is whether it is possible that plasticity also mediates
77
the long-term complications of L-Dopa therapy and, in particular, dyskinesias. It is well
accepted that, in order to avoid neuronal network destabilization, the mechanisms
underlying synaptic plasticity need to be finely regulated and, in experimental models of
L-Dopa-induced-dyskinesia, a crucial form of homeostatic synaptic plasticity,
depotentiation, is selectively lost (Picconi et al., 2003;Picconi et al., 2005;Picconi et al.,
2008). Thus, it remains possible that L-Dopa, via the continuous and uncontrolled
increase of the strength of GABAergic synapses onto output nuclei neurons, may lead to
progressive destabilization of postsynaptic firing rates, virtually reducing these to zero
and thus leading to pathological disinhibition of thalamic nuclei and the onset of
abnormal involuntary movements (Calabresi et al., 2009) (Figure 17).
78
Figure 17 Aberrant Plasticity in L-Dopa-induced dyskinesia. Following chronic administration of L-Dopa, uncontrolled potentiation of the GABA-mediated inhibition of the output nuclei might result in long-term suppression of firing rates, which in turn might lead to pathological disinhibition of the thalamus and the subsequent onset of pathological hyperkinetic behaviours, such as L-Dopa-induced dyskinesias. Inhibitory GABAergic connections are represented in red, excitatory glutamatergic connections in green and modulatory dopaminergic connections in black.
Studies assessing synaptic plasticity at the basal ganglia output are poised to yield
critical new insight into the pathophysiology of abnormal movements and may impact on
resolving the mechanisms underlying the effectiveness of deep brain stimulation in
movement disorders. Ultimately, the hope is that studies of human synaptic plasticity
might shed light on the complex mechanisms underlying symptoms of Parkinson’s
79
disease and the disabling long-term side effects of treatment with L-Dopa, as well as
beginning to elucidate the means by which DBS acts to normalize a pathological basal
ganglia.
80
Reference List
1. Abrams TW (1985) Activity-dependent presynaptic facilitation: an associative mechanism in Aplysia. Cell Mol Neurobiol 5: 123-145.
2. Aceves J, Floran B, Martinez-Fong D, Sierra A, Hernandez S, Mariscal S (1991) L-dopa stimulates the release of [3H]gamma-aminobutyric acid in the basal ganglia of 6-hydroxydopamine lesioned rats. Neurosci Lett 121: 223-226.
3. Aceves J, Floran B, Sierra A, Mariscal S (1995) D-1 receptor mediated modulation of the release of gamma-aminobutyric acid by endogenous dopamine in the basal ganglia of the rat. Prog Neuropsychopharmacol Biol Psychiatry 19: 727-739.
4. Ahlskog JE (2003) Parkinson's disease: is the initial treatment established? Curr Neurol Neurosci Rep 3: 289-295.
5. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366-375.
6. Altar CA, Hauser K (1987) Topography of substantia nigra innervation by D1 receptor-containing striatal neurons. Brain Res 410: 1-11.
7. Anderson ME, Postupna N, Ruffo M (2003) Effects of high-frequency stimulation in the internal globus pallidus on the activity of thalamic neurons in the awake monkey. J Neurophysiol 89: 1150-1160.
8. Andersson DR, Nissbrandt H, Bergquist F (2006) Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 24: 617-624.
9. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, Burbaud P (2004) Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72: 195-221.
10. Arias-Montano JA, Floran B, Floran L, Aceves J, Young JM (2007) Dopamine D(1) receptor facilitation of depolarization-induced release of gamma-amino-butyric acid in rat striatum is mediated by the cAMP/PKA pathway and involves P/Q-type calcium channels. Synapse 61: 310-319.
11. Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR (1992) Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. Br J Neurosurg 6: 575-582.
81
12. Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (2000) Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. J Neurosci 20: 89-102.
13. Bar-Gad I, Morris G, Bergman H (2003) Information processing, dimensionality reduction and reinforcement learning in the basal ganglia. Prog Neurobiol 71: 439-473.
14. Barone P, Tucci I, Parashos SA, Chase TN (1987) D-1 dopamine receptor changes after striatal quinolinic acid lesion. Eur J Pharmacol 138: 141-145.
15. Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991: 120-131.
16. Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, Malenka RC (2000) Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat Neurosci 3: 1291-1300.
17. Beckley DJ, Panzer VP, Remler MP, Ilog LB, Bloem BR (1995) Clinical correlates of motor performance during paced postural tasks in Parkinson's disease. J Neurol Sci 132: 133-138.
18. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J (1987) Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 50: 344-346.
19. Benecke R, Rothwell JC, Dick JP, Day BL, Marsden CD (1987) Simple and complex movements off and on treatment in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 50: 296-303.
20. Berger TW (1984) Long-term potentiation of hippocampal synaptic transmission affects rate of behavioral learning. Science 224: 627-630.
21. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438.
22. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507-520.
23. Bevan MD, Magill PJ, Terman D, Bolam JP, Wilson CJ (2002) Move to the rhythm: oscillations in the subthalamic nucleus-external globus pallidus network. Trends Neurosci 25: 525-531.
24. Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2: 577-588.
82
25. Bito H, Deisseroth K, Tsien RW (1996) CREB phosphorylation and dephosphorylation: a Ca(2+)- and stimulus duration-dependent switch for hippocampal gene expression. Cell 87: 1203-1214.
26. Bliss TV, Lomo T (1973) Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 232: 331-356.
27. Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000) Synaptic organisation of the basal ganglia. J Anat 196 ( Pt 4): 527-542.
28. Boraud T, Bezard E, Bioulac B, Gross C (1996) High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey. Neurosci Lett 215: 17-20.
29. Boshes B (1981) Sinemet and the treatment of Parkinsonism. Ann Intern Med 94: 364-370.
30. Braunewell KH, Manahan-Vaughan D (2001) Long-term depression: a cellular basis for learning? Rev Neurosci 12: 121-140.
31. Brown P (2003) Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord 18: 357-363.
32. Brown P, Eusebio A (2008) Paradoxes of functional neurosurgery: clues from basal ganglia recordings. Mov Disord 23: 12-20.
33. Brown P, Mazzone P, Oliviero A, Altibrandi MG, Pilato F, Tonali PA, Di L, V (2004) Effects of stimulation of the subthalamic area on oscillatory pallidal activity in Parkinson's disease. Exp Neurol 188: 480-490.
34. Burleigh-Jacobs A, Horak FB, Nutt JG, Obeso JA (1997) Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers. Mov Disord 12: 206-215.
35. Caillard O, Ben Ari Y, Gaiarsa JL (1999a) Long-term potentiation of GABAergic synaptic transmission in neonatal rat hippocampus. J Physiol 518 ( Pt 1): 109-119.
36. Caillard O, Ben Ari Y, Gaiarsa JL (1999b) Mechanisms of induction and expression of long-term depression at GABAergic synapses in the neonatal rat hippocampus. J Neurosci 19: 7568-7577.
37. Calabresi P, Gubellini P, Centonze D, Picconi B, Bernardi G, Chergui K, Svenningsson P, Fienberg AA, Greengard P (2000) Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J Neurosci 20: 8443-8451.
83
38. Calabresi P, Maj R, Mercuri NB, Bernardi G (1992) Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci Lett 142: 95-99.
39. Calabresi P, Mercuri NB, Di Filippo M (2009) Synaptic plasticity, dopamine and Parkinson's disease: one step ahead. Brain 132: 285-287.
40. Calabresi P, Picconi B, Tozzi A, Di Filippo M (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30: 211-219.
41. Calabresi P, Pisani A, Mercuri NB, Bernardi G (1994) Post-receptor mechanisms underlying striatal long-term depression. J Neurosci 14: 4871-4881.
42. Calabresi P, Saiardi A, Pisani A, Baik JH, Centonze D, Mercuri NB, Bernardi G, Borrelli E (1997) Abnormal synaptic plasticity in the striatum of mice lacking dopamine D2 receptors. J Neurosci 17: 4536-4544.
43. Carroll RC, Lissin DV, von Zastrow M, Nicoll RA, Malenka RC (1999) Rapid redistribution of glutamate receptors contributes to long-term depression in hippocampal cultures. Nat Neurosci 2: 454-460.
44. Centonze D, Grande C, Saulle E, Martin AB, Gubellini P, Pavon N, Pisani A, Bernardi G, Moratalla R, Calabresi P (2003) Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23: 8506-8512.
45. Centonze D, Gubellini P, Picconi B, Calabresi P, Giacomini P, Bernardi G (1999) Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 82: 3575-3579.
46. Chastan N, Westby GW, Yelnik J, Bardinet E, Do MC, Agid Y, Welter ML (2009) Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease. Brain 132: 172-184.
47. Cheramy A, Leviel V, Glowinski J (1981) Dendritic release of dopamine in the substantia nigra. Nature 289: 537-542.
48. Chung HJ, Steinberg JP, Huganir RL, Linden DJ (2003) Requirement of AMPA receptor GluR2 phosphorylation for cerebellar long-term depression. Science 300: 1751-1755.
49. Contractor A, Swanson G, Heinemann SF (2001) Kainate receptors are involved in short- and long-term plasticity at mossy fiber synapses in the hippocampus. Neuron 29: 209-216.
50. Cooke SF, Bliss TV (2006) Plasticity in the human central nervous system. Brain 129: 1659-1673.
84
51. Cookson MR (2005) The biochemistry of Parkinson's disease. Annu Rev Biochem 74: 29-52.
52. Costa RM, Lin SC, Sotnikova TD, Cyr M, Gainetdinov RR, Caron MG, Nicolelis MA (2006) Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron 52: 359-369.
53. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374-379.
54. Cummings JA, Mulkey RM, Nicoll RA, Malenka RC (1996) Ca2+ signaling requirements for long-term depression in the hippocampus. Neuron 16: 825-833.
55. Cummings JL (1999) Understanding Parkinson disease. JAMA 281: 376-378.
56. Damier P, Hirsch EC, Agid Y, Graybiel AM (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 ( Pt 8): 1437-1448.
57. Dash PK, Karl KA, Colicos MA, Prywes R, Kandel ER (1991) cAMP response element-binding protein is activated by Ca2+/calmodulin- as well as cAMP-dependent protein kinase. Proc Natl Acad Sci U S A 88: 5061-5065.
58. Davis S, Butcher SP, Morris RG (1992) The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J Neurosci 12: 21-34.
59. Dawson VL, Dawson TM (2004) Deadly conversations: nuclear-mitochondrial cross-talk. J Bioenerg Biomembr 36: 287-294.
60. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13: 281-285.
61. Deniau JM, Mailly P, Maurice N, Charpier S (2007) The pars reticulata of the substantia nigra: a window to basal ganglia output. Prog Brain Res 160: 151-172.
62. Dorval AD, Russo GS, Hashimoto T, Xu W, Grill WM, Vitek JL (2008) Deep brain stimulation reduces neuronal entropy in the MPTP-primate model of Parkinson's disease. J Neurophysiol 100: 2807-2818.
63. Dostrovsky JO, Hutchison WD, Lozano AM (2002) The globus pallidus, deep brain stimulation, and Parkinson's disease. Neuroscientist 8: 284-290.
64. Dostrovsky JO, Levy R, Wu JP, Hutchison WD, Tasker RR, Lozano AM (2000) Microstimulation-induced inhibition of neuronal firing in human globus pallidus. J Neurophysiol 84: 570-574.
85
65. Dudek SM, Bear MF (1992) Homosynaptic long-term depression in area CA1 of hippocampus and effects of N-methyl-D-aspartate receptor blockade. Proc Natl Acad Sci U S A 89: 4363-4367.
66. Dunnett S (2003) L-DOPA, dyskinesia and striatal plasticity. Nat Neurosci 6: 437-438.
67. Engert F, Bonhoeffer T (1999) Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 399: 66-70.
68. Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62: 353-357.
69. Eusebio A, Brown P (2009) Synchronisation in the beta frequency-band - The bad boy of parkinsonism or an innocent bystander? Exp Neurol 217: 1-3.
70. Filali M, Hutchison WD, Palter VN, Lozano AM, Dostrovsky JO (2004) Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus. Exp Brain Res 156: 274-281.
71. Fitzjohn SM, Palmer MJ, May JE, Neeson A, Morris SA, Collingridge GL (2001) A characterisation of long-term depression induced by metabotropic glutamate receptor activation in the rat hippocampus in vitro. J Physiol 537: 421-430.
72. Floran B, Aceves J, Sierra A, Martinez-Fong D (1990) Activation of D1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci Lett 116: 136-140.
73. Francois C, Percheron G, Yelnik J (1984) Localization of nigrostriatal, nigrothalamic and nigrotectal neurons in ventricular coordinates in macaques. Neuroscience 13: 61-76.
74. Francois C, Tande D, Yelnik J, Hirsch EC (2002) Distribution and morphology of nigral axons projecting to the thalamus in primates. J Comp Neurol 447: 249-260.
75. Gaiarsa JL (2004) Plasticity of GABAergic synapses in the neonatal rat hippocampus. J Cell Mol Med 8: 31-37.
76. Gaiarsa JL, Caillard O, Ben Ari Y (2002) Long-term plasticity at GABAergic and glycinergic synapses: mechanisms and functional significance. Trends Neurosci 25: 564-570.
77. Galvan A, Kuwajima M, Smith Y (2006) Glutamate and GABA receptors and transporters in the basal ganglia: what does their subsynaptic localization reveal about their function? Neuroscience 143: 351-375.
78. Geffen LB, Jessell TM, Cuello AC, Iversen LL (1976) Release of dopamine from dendrites in rat substantia nigra. Nature 260: 258-260.
86
79. Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology 38: 1402-1406.
80. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9: 589-595.
81. Giuffrida A, Parsons LH, Kerr TM, Rodriguez dF, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2: 358-363.
82. Gonzalez GA, Montminy MR (1989) Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59: 675-680.
83. Graybiel AM, Aosaki T, Flaherty AW, Kimura M (1994) The basal ganglia and adaptive motor control. Science 265: 1826-1831.
84. Grofova I, Zhou M (1998) Nigral innervation of cholinergic and glutamatergic cells in the rat mesopontine tegmentum: light and electron microscopic anterograde tracing and immunohistochemical studies. J Comp Neurol 395: 359-379.
85. Guzman JN, Hernandez A, Galarraga E, Tapia D, Laville A, Vergara R, Aceves J, Bargas J (2003) Dopaminergic modulation of axon collaterals interconnecting spiny neurons of the rat striatum. J Neurosci 23: 8931-8940.
86. Hammond C, Bergman H, Brown P (2007) Pathological synchronization in Parkinson's disease: networks, models and treatments. Trends Neurosci 30: 357-364.
87. Hashimoto T, Elder CM, Okun MS, Patrick SK, Vitek JL (2003) Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J Neurosci 23: 1916-1923.
88. Hashimotodani Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima T, Araishi K, Shin HS, Kano M (2005) Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron 45: 257-268.
89. Hebb DO (1949) The organization of behaviour. New York: John Wiley and Sons.
90. Hikosaka O, Takikawa Y, Kawagoe R (2000) Role of the basal ganglia in the control of purposive saccadic eye movements. Physiol Rev 80: 953-978.
91. Hrabetova S, Sacktor TC (2001) Transient translocation of conventional protein kinase C isoforms and persistent downregulation of atypical protein kinase Mzeta in long-term depression. Brain Res Mol Brain Res 95: 146-152.
87
92. Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50: 140-148.
93. Hutchison WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, Lozano AM (1998) Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 44: 622-628.
94. Hutchison WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE (1997) Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 42: 767-775.
95. Hutchison WD, Lozano AM (2000) Microelectrode recordings in movement disorder surgery. Progr Neurol Surg 15: 103-117.
96. Ito M, Sakurai M, Tongroach P (1982) Climbing fibre induced depression of both mossy fibre responsiveness and glutamate sensitivity of cerebellar Purkinje cells. J Physiol 324: 113-134.
97. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35: 1503-1519.
98. Jaggi JL, Umemura A, Hurtig HI, Siderowf AD, Colcher A, Stern MB, Baltuch GH (2004) Bilateral stimulation of the subthalamic nucleus in Parkinson's disease: surgical efficacy and prediction of outcome. Stereotact Funct Neurosurg 82: 104-114.
99. Junghanns S, Glockler T, Reichmann H (2004) Switching and combining of dopamine agonists. J Neurol 251 Suppl 6: VI/19-VI/23.
100. Kameyama K, Lee HK, Bear MF, Huganir RL (1998) Involvement of a postsynaptic protein kinase A substrate in the expression of homosynaptic long-term depression. Neuron 21: 1163-1175.
101. Kandler K, Katz LC, Kauer JA (1998) Focal photolysis of caged glutamate produces long-term depression of hippocampal glutamate receptors. Nat Neurosci 1: 119-123.
102. Kannenberg K, Sieghart W, Reuter H (1999) Clusters of GABAA receptors on cultured hippocampal cells correlate only partially with functional synapses. Eur J Neurosci 11: 1256-1264.
103. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105.
88
104. Kasahara J, Fukunaga K, Miyamoto E (2001) Activation of calcium/calmodulin-dependent protein kinase IV in long term potentiation in the rat hippocampal CA1 region. J Biol Chem 276: 24044-24050.
105. Kawaguchi Y, Wilson CJ, Emson PC (1990) Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 10: 3421-3438.
106. Kerr JN, Wickens JR (2001) Dopamine D-1/D-5 receptor activation is required for long-term potentiation in the rat neostriatum in vitro. J Neurophysiol 85: 117-124.
107. Kish SJ, Shannak K, Hornykiewicz O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
108. Kita H, Kitai ST (1987) Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol 260: 435-452.
109. Kita H, Nambu A, Kaneda K, Tachibana Y, Takada M (2004) Role of ionotropic glutamatergic and GABAergic inputs on the firing activity of neurons in the external pallidum in awake monkeys. J Neurophysiol 92: 3069-3084.
110. Kittler JT, Delmas P, Jovanovic JN, Brown DA, Smart TG, Moss SJ (2000) Constitutive endocytosis of GABAA receptors by an association with the adaptin AP2 complex modulates inhibitory synaptic currents in hippocampal neurons. J Neurosci 20: 7972-7977.
111. Klein C, Lohmann-Hedrich K (2007) Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 20: 453-464.
112. Kleiner-Fisman G, Fisman DN, Sime E, Saint-Cyr JA, Lozano AM, Lang AE (2003) Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg 99: 489-495.
113. Kleiner-Fisman G, Herzog J, Fisman DN, Tamma F, Lyons KE, Pahwa R, Lang AE, Deuschl G (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl 14: S290-S304.
114. Korf J, Zieleman M, Westerink BH (1976) Dopamine release in substantia nigra? Nature 260: 257-258.
115. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, Koudsie A, Limousin PD, Benazzouz A, LeBas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349: 1925-1934.
89
116. Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445: 643-647.
117. Kreitzer AC, Malenka RC (2008) Striatal plasticity and basal ganglia circuit function. Neuron 60: 543-554.
118. Kuhn AA, Kupsch A, Schneider GH, Brown P (2006) Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci 23: 1956-1960.
119. Kuhn AA, Trottenberg T, Kivi A, Kupsch A, Schneider GH, Brown P (2005) The relationship between local field potential and neuronal discharge in the subthalamic nucleus of patients with Parkinson's disease. Exp Neurol 194: 212-220.
120. Lafreniere-Roula M, Hutchison WD, Lozano AM, Hodaie M, Dostrovsky JO (2009) Microstimulation-induced inhibition as a tool to aid targeting the ventral border of the subthalamic nucleus. J Neurosurg.
121. Laitinen LV, Bergenheim AT, Hariz MI (1992) Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76: 53-61.
122. Lang AE, Lozano AM (1998a) Parkinson's disease. First of two parts. N Engl J Med 339: 1044-1053.
123. Lang AE, Lozano AM (1998b) Parkinson's disease. Second of two parts. N Engl J Med 339: 1130-1143.
124. Lauri SE, Bortolotto ZA, Nistico R, Bleakman D, Ornstein PL, Lodge D, Isaac JT, Collingridge GL (2003) A role for Ca2+ stores in kainate receptor-dependent synaptic facilitation and LTP at mossy fiber synapses in the hippocampus. Neuron 39: 327-341.
125. Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL (2000) Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature 405: 955-959.
126. Lee HK, Kameyama K, Huganir RL, Bear MF (1998) NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron 21: 1151-1162.
127. Lee SH, Liu L, Wang YT, Sheng M (2002) Clathrin adaptor AP2 and NSF interact with overlapping sites of GluR2 and play distinct roles in AMPA receptor trafficking and hippocampal LTD. Neuron 36: 661-674.
128. Lemaire JJ, Coste J, Ouchchane L, Caire F, Nuti C, Derost P, Cristini V, Gabrillargues J, Hemm S, Durif F, Chazal J (2007) Brain mapping in stereotactic
90
surgery: a brief overview from the probabilistic targeting to the patient-based anatomic mapping. Neuroimage 37 Suppl 1: S109-S115.
129. Levy R, Hutchison WD, Lozano AM, Dostrovsky JO (2002) Synchronized neuronal discharge in the basal ganglia of parkinsonian patients is limited to oscillatory activity. J Neurosci 22: 2855-2861.
130. Li R, Dozmorov M, Hellberg F, Tian Y, Jilderos B, Wigstrom H (2004) Characterization of NMDA induced depression in rat hippocampus: involvement of AMPA and NMDA receptors. Neurosci Lett 357: 87-90.
131. Limousin P, Martinez-Torres I (2008) Deep brain stimulation for Parkinson's disease. Neurotherapeutics 5: 309-319.
132. Lozano AM, Mahant N (2004) Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat Disord 10 Suppl 1: S49-S57.
133. Lu YM, Mansuy IM, Kandel ER, Roder J (2000) Calcineurin-mediated LTD of GABAergic inhibition underlies the increased excitability of CA1 neurons associated with LTP. Neuron 26: 197-205.
134. Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. Neuron 44: 5-21.
135. Malinow R, Malenka RC (2002) AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 25: 103-126.
136. Mallet N, Pogosyan A, Marton LF, Bolam JP, Brown P, Magill PJ (2008a) Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity. J Neurosci 28: 14245-14258.
137. Mallet N, Pogosyan A, Sharott A, Csicsvari J, Bolam JP, Brown P, Magill PJ (2008b) Disrupted dopamine transmission and the emergence of exaggerated beta oscillations in subthalamic nucleus and cerebral cortex. J Neurosci 28: 4795-4806.
138. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD (1992) Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 ( Pt 2): 333-342.
139. Marsden CD, Obeso JA (1994) The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117 ( Pt 4): 877-897.
140. Martella G, Platania P, Vita D, Sciamanna G, Cuomo D, Tassone A, Tscherter A, Kitada T, Bonsi P, Shen J, Pisani A (2009) Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin. Exp Neurol 215: 388-396.
91
141. Martin KC, Michael D, Rose JC, Barad M, Casadio A, Zhu H, Kandel ER (1997) MAP kinase translocates into the nucleus of the presynaptic cell and is required for long-term facilitation in Aplysia. Neuron 18: 899-912.
142. Mink JW (1996) The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 50: 381-425.
143. Mink JW (2003) The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 60: 1365-1368.
144. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
145. Montminy MR, Bilezikjian LM (1987) Binding of a nuclear protein to the cyclic-AMP response element of the somatostatin gene. Nature 328: 175-178.
146. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R (2006) Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 129: 1059-1069.
147. Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 53: 85-90.
148. Moser EI, Moser MB, Andersen P (1994) Potentiation of dentate synapses initiated by exploratory learning in rats: dissociation from brain temperature, motor activity, and arousal. Learn Mem 1: 55-73.
149. Nakamura K, Hikosaka O (2006a) Facilitation of saccadic eye movements by postsaccadic electrical stimulation in the primate caudate. J Neurosci 26: 12885-12895.
150. Nakamura K, Hikosaka O (2006b) Role of dopamine in the primate caudate nucleus in reward modulation of saccades. J Neurosci 26: 5360-5369.
151. Nambu A, Tokuno H, Hamada I, Kita H, Imanishi M, Akazawa T, Ikeuchi Y, Hasegawa N (2000) Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 84: 289-300.
152. Nicoll RA, Kauer JA, Malenka RC (1988) The current excitement in long-term potentiation. Neuron 1: 97-103.
153. Nicoll RA, Malenka RC (1999) Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 868: 515-525.
154. Nusser Z, Hajos N, Somogyi P, Mody I (1998) Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses. Nature 395: 172-177.
92
155. Nutt JG, Carter JH, Woodward WR (1995) Long-duration response to levodopa. Neurology 45: 1613-1616.
156. Obeso JA, Olanow CW, Nutt JG (2000a) Levodopa motor complications in Parkinson's disease. Trends Neurosci 23: S2-S7.
157. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW (2000b) Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23: S8-19.
158. Oliet SH, Malenka RC, Nicoll RA (1997) Two distinct forms of long-term depression coexist in CA1 hippocampal pyramidal cells. Neuron 18: 969-982.
159. Pahapill PA, Lozano AM (2000) The pedunculopontine nucleus and Parkinson's disease. Brain 123 ( Pt 9): 1767-1783.
160. Pahwa R, Wilkinson SB, Overman J, Lyons KE (2005) Preoperative clinical predictors of response to bilateral subthalamic stimulation in patients with Parkinson's disease. Stereotact Funct Neurosurg 83: 80-83.
161. Parent A, Hazrati LN (1995a) Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 20: 91-127.
162. Parent A, Hazrati LN (1995b) Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 20: 128-154.
163. Parkinson J (1817) An Essay on the Shaking Palsy. London, England: Sherwood, Neely & Jones.
164. Perlmutter JS, Mink JW (2006) Deep brain stimulation. Annu Rev Neurosci 29: 229-257.
165. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6: 501-506.
166. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela CM, Calabresi P (2008) l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29: 327-335.
167. Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, Calabresi P (2005) Pathological synaptic plasticity in the striatum: implications for Parkinson's disease. Neurotoxicology 26: 779-783.
168. Pittenger C, Kandel ER (2003) In search of general mechanisms for long-lasting plasticity: Aplysia and the hippocampus. Philos Trans R Soc Lond B Biol Sci 358: 757-763.
93
169. Precht W, Yoshida M (1971) Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin. Brain Res 32: 229-233.
170. Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD (2009) Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain 132: 309-318.
171. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86: 122-127.
172. Radnikow G, Misgeld U (1998) Dopamine D1 receptors facilitate GABAA synaptic currents in the rat substantia nigra pars reticulata. J Neurosci 18: 2009-2016.
173. Rammes G, Palmer M, Eder M, Dodt HU, Zieglgansberger W, Collingridge GL (2003) Activation of mGlu receptors induces LTD without affecting postsynaptic sensitivity of CA1 neurons in rat hippocampal slices. J Physiol 546: 455-460.
174. Raymond CR (2007) LTP forms 1, 2 and 3: different mechanisms for the "long" in long-term potentiation. Trends Neurosci 30: 167-175.
175. Reid CA, Dixon DB, Takahashi M, Bliss TV, Fine A (2004) Optical quantal analysis indicates that long-term potentiation at single hippocampal mossy fiber synapses is expressed through increased release probability, recruitment of new release sites, and activation of silent synapses. J Neurosci 24: 3618-3626.
176. Ribak CE, Vaughn JE, Barber RP (1981) Immunocytochemical localization of GABAergic neurones at the electron microscopical level. Histochem J 13: 555-582.
177. Ribak CE, Vaughn JE, Roberts E (1979) The GABA neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry. J Comp Neurol 187: 261-283.
178. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48: 363-368.
179. Robertson GS, Damsma G, Fibiger HC (1991) Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci 11: 2209-2216.
180. Ronesi J, Gerdeman GL, Lovinger DM (2004) Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24: 1673-1679.
94
181. Saliba RS, Michels G, Jacob TC, Pangalos MN, Moss SJ (2007) Activity-dependent ubiquitination of GABA(A) receptors regulates their accumulation at synaptic sites. J Neurosci 27: 13341-13351.
182. Schmitz D, Mellor J, Breustedt J, Nicoll RA (2003) Presynaptic kainate receptors impart an associative property to hippocampal mossy fiber long-term potentiation. Nat Neurosci 6: 1058-1063.
183. Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 123 ( Pt 11): 2297-2305.
184. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36: 241-263.
185. Schupbach WM, Chastan N, Welter ML, Houeto JL, Mesnage V, Bonnet AM, Czernecki V, Maltete D, Hartmann A, Mallet L, Pidoux B, Dormont D, Navarro S, Cornu P, Mallet A, Agid Y (2005) Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 76: 1640-1644.
186. Sharott A, Magill PJ, Harnack D, Kupsch A, Meissner W, Brown P (2005) Dopamine depletion increases the power and coherence of beta-oscillations in the cerebral cortex and subthalamic nucleus of the awake rat. Eur J Neurosci 21: 1413-1422.
187. Shen W, Flajolet M, Greengard P, Surmeier DJ (2008) Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321: 848-851.
188. Smith Y, Bolam JP (1989) Neurons of the substantia nigra reticulata receive a dense GABA-containing input from the globus pallidus in the rat. Brain Res 493: 160-167.
189. Sparks DL, Mays LE (1990b) Signal transformations required for the generation of saccadic eye movements. Annu Rev Neurosci 13: 309-336.
190. Sparks DL, Mays LE (1990a) Signal transformations required for the generation of saccadic eye movements. Annu Rev Neurosci 13: 309-336.
191. Squire LR, Kandel ER (1999) Memory: From Mind to Molecules. New York: Scientific American Library.
192. Stefan K, Kunesch E, Benecke R, Cohen LG, Classen J (2002) Mechanisms of enhancement of human motor cortex excitability induced by interventional paired associative stimulation. J Physiol 543: 699-708.
193. Stefan K, Kunesch E, Cohen LG, Benecke R, Classen J (2000) Induction of plasticity in the human motor cortex by paired associative stimulation. Brain 123 Pt 3: 572-584.
95
194. Surmeier DJ, Song WJ, Yan Z (1996) Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16: 6579-6591.
195. Takakusaki K, Habaguchi T, Ohtinata-Sugimoto J, Saitoh K, Sakamoto T (2003) Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction. Neuroscience 119: 293-308.
196. Takakusaki K, Saitoh K, Harada H, Kashiwayanagi M (2004) Role of basal ganglia-brainstem pathways in the control of motor behaviors. Neurosci Res 50: 137-151.
197. Tan Y, Hori N, Carpenter DO (2003) The mechanism of presynaptic long-term depression mediated by group I metabotropic glutamate receptors. Cell Mol Neurobiol 23: 187-203.
198. Tanzi E (1893) I fatti e le induzioni nell'odierna istologia del sistema nervosa. Riv Sperim Feniatria Medic Leg 19: 419-472.
199. Terman D, Rubin JE, Yew AC, Wilson CJ (2002) Activity patterns in a model for the subthalamopallidal network of the basal ganglia. J Neurosci 22: 2963-2976.
200. Thanvi BR, Lo TC (2004) Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad Med J 80: 452-458.
201. Timmerman W, Abercrombie ED (1996) Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. Synapse 23: 280-291.
202. Tong G, Malenka RC, Nicoll RA (1996) Long-term potentiation in cultures of single hippocampal granule cells: a presynaptic form of plasticity. Neuron 16: 1147-1157.
203. Ueki Y, Mima T, Kotb MA, Sawada H, Saiki H, Ikeda A, Begum T, Reza F, Nagamine T, Fukuyama H (2006) Altered plasticity of the human motor cortex in Parkinson's disease. Ann Neurol 59: 60-71.
204. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367: 69-93.
205. van Dam EJ, Ruiter B, Kamal A, Ramakers GM, Gispen WH, de Graan PN (2002) N-methyl-D-aspartate-induced long-term depression is associated with a decrease in postsynaptic protein kinase C substrate phosphorylation in rat hippocampal slices. Neurosci Lett 320: 129-132.
206. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ (1997) Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41: 58-64.
96
207. Wang JH, Stelzer A (1996) Shared calcium signaling pathways in the induction of long-term potentiation and synaptic disinhibition in CA1 pyramidal cell dendrites. J Neurophysiol 75: 1687-1702.
208. Wang YT, Linden DJ (2000) Expression of cerebellar long-term depression requires postsynaptic clathrin-mediated endocytosis. Neuron 25: 635-647.
209. Weinberger M, Hamani C, Hutchison WD, Moro E, Lozano AM, Dostrovsky JO (2008b) Pedunculopontine nucleus microelectrode recordings in movement disorder patients. Exp Brain Res 188: 165-174.
210. Weinberger M, Hamani C, Hutchison WD, Moro E, Lozano AM, Dostrovsky JO (2008a) Pedunculopontine nucleus microelectrode recordings in movement disorder patients. Exp Brain Res 188: 165-174.
211. Weinberger M, Hutchison WD, Dostrovsky JO (2009) Pathological subthalamic nucleus oscillations in PD: Can they be the cause of bradykinesia and akinesia? Exp Neurol.
212. Weinberger M, Mahant N, Hutchison WD, Lozano AM, Moro E, Hodaie M, Lang AE, Dostrovsky JO (2006) Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol 96: 3248-3256.
213. Wichmann T, Kliem MA (2004) Neuronal activity in the primate substantia nigra pars reticulata during the performance of simple and memory-guided elbow movements. J Neurophysiol 91: 815-827.
214. Wichmann T, Kliem MA, DeLong MR (2001) Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp Neurol 167: 410-424.
215. Wickens JR (2009) Synaptic plasticity in the basal ganglia. Behav Brain Res 199: 119-128.
216. Wolters A, Sandbrink F, Schlottmann A, Kunesch E, Stefan K, Cohen LG, Benecke R, Classen J (2003) A temporally asymmetric Hebbian rule governing plasticity in the human motor cortex. J Neurophysiol 89: 2339-2345.
217. Wooten GF (2001) Anatomy and function of dopamine receptors: understanding the pathophysiology of fluctuations in Parkinson's disease. Parkinsonism Relat Disord 8: 79-83.
218. Xu W, Russo GS, Hashimoto T, Zhang J, Vitek JL (2008) Subthalamic nucleus stimulation modulates thalamic neuronal activity. J Neurosci 28: 11916-11924.
97
219. Yamamoto KK, Gonzalez GA, Biggs WH, III, Montminy MR (1988) Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 334: 494-498.
220. Yang SN, Tang YG, Zucker RS (1999) Selective induction of LTP and LTD by postsynaptic [Ca2+]i elevation. J Neurophysiol 81: 781-787.
221. Yin HH, Knowlton BJ, Balleine BW (2006) Inactivation of dorsolateral striatum enhances sensitivity to changes in the action-outcome contingency in instrumental conditioning. Behav Brain Res 166: 189-196.
222. Yoshida M, Precht W (1971) Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers. Brain Res 32: 225-228.
223. Yuill GM (1976) Letter: Effect of levodopa on Parkinsonian tremor. Br Med J 1: 283-284.
224. Zakharenko SS, Zablow L, Siegelbaum SA (2002) Altered presynaptic vesicle release and cycling during mGluR-dependent LTD. Neuron 35: 1099-1110.
225. Zhang ZX, Roman GC (1993) Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12: 195-208.
226. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM (1990) Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 13: 290-296.
227. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annu Rev Physiol 64: 355-405.
top related